{"questions": [
    {
        "body": "Is Rheumatoid Arthritis more common in men or women?", 
        "concepts": [
            "http://www.disease-ontology.org/api/metadata/DOID:7148", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001171", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012217", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013167", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015535"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23217568", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22853635", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21340496", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20889597", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20810033", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19158113", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18759162", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17965425", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16418123", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15083883", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12723987", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1563036"
        ], 
        "exact_answer": [
            "Women"
        ], 
        "id": "5118dd1305c10fae75000001", 
        "ideal_answer": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217568", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 591, 
                "offsetInEndSection": 678, 
                "text": "Our results show a high prevalence of RA in LAC women with a ratio of 5.2 women per man"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217568", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1140, 
                "offsetInEndSection": 1394, 
                "text": "RA in LAC women is not only more common but presents with some clinical characteristics that differ from RA presentation in men. Some of those characteristics could explain the high rates of disability and worse prognosis observed in women with RA in LAC"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22853635", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 559, 
                "offsetInEndSection": 718, 
                "text": "The expression and clinical course of RA are influenced by gender. In developed countries the prevalence of RA is 0,5 to 1.0%, with a male:female ratio of 1:3."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22853635", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 897, 
                "offsetInEndSection": 1031, 
                "text": "women were found to have higher disease activity scores, more pain and greater loss of function, both in early and established disease"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340496", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 993, 
                "offsetInEndSection": 1062, 
                "text": "Intense anti-CCP2 reaction was 19.8-fold higher in females vs. males,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889597", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 911, 
                "offsetInEndSection": 944, 
                "text": " men (n = 67) and women (n = 225)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889597", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1808, 
                "offsetInEndSection": 1943, 
                "text": " Responses to treatment over time were better among men in this prebiologic era; women had worse progression despite similar treatment."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810033", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1550, 
                "offsetInEndSection": 1629, 
                "text": "BMI appears to be associated with RA disease activity in women, but not in men."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810033", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 729, 
                "offsetInEndSection": 785, 
                "text": "A total of 5,161 RA patients (4,082 women and 1,079 men)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158113", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 561, 
                "offsetInEndSection": 744, 
                "text": "In women the DAS28 was significantly higher than in men due to higher scores for general health and tender joints. Likewise, HAQ and VAS pain were rated significantly higher in women."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759162", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 263, 
                "offsetInEndSection": 285, 
                "text": "432 females, 125 males"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965425", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 862, 
                "offsetInEndSection": 1017, 
                "text": "ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1563036", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 162, 
                "text": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome."
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12723987", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 7, 
                "offsetInEndSection": 89, 
                "text": "The mean age of the patients was 62 years (range 19\u201396 years) and 71% were female;"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15083883", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 688, 
                "offsetInEndSection": 830, 
                "text": "The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16418123", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 453, 
                "offsetInEndSection": 514, 
                "text": "in 244 female and 91 male patients with rheumatoid arthritis."
            }
        ], 
        "type": "factoid"
    }, 
    {
        "body": "Are there any DNMT3 proteins present in plants?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/CMT1_ARATH", 
            "http://www.uniprot.org/uniprot/CMT2_ARATH", 
            "http://www.uniprot.org/uniprot/CMT3_ARATH"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21150311", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10781108", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15946751", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20505370", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23021223", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22058406", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18488247", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17660570", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11487702", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11459824", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15282033", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12151602", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12121623", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9584105"
        ], 
        "exact_answer": "Yes.", 
        "id": "511a16f9df1ebcce7d000005", 
        "ideal_answer": "Yes. The plant DOMAINS REARRANGED METHYLTRANSFERASE2 (DRM2) is a homolog of the mammalian de novo methyltransferase DNMT3. DRM2 contains a novel arrangement of the motifs required for DNA methyltransferase catalytic activity.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150311", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 151, 
                "text": "De novo DNA methylation in Arabidopsis thaliana is catalyzed by the methyltransferase DRM2, a homolog of the mammalian de novo methyltransferase DNMT3."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1131, 
                "offsetInEndSection": 1666, 
                "text": "Three functional classes of DNA methyltransferase exist in A.thaliana; METHYLTRANSFERASE1 (MET1) (orthologous to mammalian Dnmt1) which maintains CG methylation, CHROMOMETHYLASE3 (CMT3) (plant specific) which maintains methylation in non-CG sequence contexts and DOMAINS REARRANGED METHYLTRANSFERASE2 (DRM2) (orthologous to Dnmt3a/Dnmt3b) which both de novo methylates DNA and maintains non-CG methylation redundantly with CMT3 [2]. The drm2 mutation blocks all de novo DNA methylation driven by repeat containing transgenes [15]\u2013[17]."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060858", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2763, 
                "offsetInEndSection": 2909, 
                "text": "The mammalian DRM2 orthologs, Dnmt3a and Dnmt3b, are required to de novo methylate integrated retroviral sequences and imprinted genes [38], [39]."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10781108", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 387, 
                "offsetInEndSection": 851, 
                "text": "Here we describe DNA methyltransferase genes from both Arabidopsis and maize that show a high level of sequence similarity to Dnmt3, suggesting that they encode plant de novo methyltransferases. Relative to all known eukaryotic methyltransferases, these plant proteins contain a novel arrangement of the motifs required for DNA methyltransferase catalytic activity. The N termini of these methyltransferases contain a series of ubiquitin-associated (UBA) domains. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15946751", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 365, 
                "offsetInEndSection": 519, 
                "text": "BLASTX searches and phylogenetic analysis suggested that five cDNAs belonged to four classes (Dnmt1, Dnmt2, CMT and Dnmt3) of DNA methyltransferase genes."
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "What is the most prominent sequence consensus for the polyadenylation site?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026723", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011061", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039221", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D039104", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016384", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011063", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012313", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043631", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=1900363"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/1915889", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1993703", 
            "http://www.ncbi.nlm.nih.gov/pubmed/6194440", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7901430", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1712333", 
            "http://www.ncbi.nlm.nih.gov/pubmed/2513486"
        ], 
        "exact_answer": [
            [
                "AATAAA"
            ], 
            [
                "AAUAAA"
            ]
        ], 
        "id": "5133b9455274a5fb0700000c", 
        "ideal_answer": "Functional polyadenylation [poly(A)] sites consist of two sequence elements, the AAUAAA and G/U box signals, that closely flank the site of mRNA 3'-end formation. The canonical polyadenylation signal sequence AATAAA", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1915889", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 364, 
                "offsetInEndSection": 417, 
                "text": "the cannonical polyadenylation signal sequence AATAAA"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1993703", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1178, 
                "offsetInEndSection": 1235, 
                "text": "Two AATAAA motifs are coded in the last exon of this gene"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/6194440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 236, 
                "offsetInEndSection": 407, 
                "text": "The results demonstrate that the intact AAUAAA is not required for RNA polyadenylation but is required for the cleavage step preceding polyadenylation to occur efficiently"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7901430", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 464, 
                "offsetInEndSection": 532, 
                "text": "the early poly(A) consensus signal was mutated from AAUAAA to UGUAAA"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1712333", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 161, 
                "text": "Functional polyadenylation [poly(A)] sites consist of two sequence elements, the AAUAAA and G/U box signals, that closely flank the site of mRNA 3'-end formation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1712333", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 849, 
                "offsetInEndSection": 944, 
                "text": "the appropriate spacing of the AAUAAA and G/U box signals is critical for poly(A) site function"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2513486", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 189, 
                "offsetInEndSection": 320, 
                "text": " Two AATAAA hexanucleotide sequences are present in the 2092 nucleotide interval. The first one functions as the major polyA signal"
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "What is the function of the mammalian gene Irg1?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/IRG1_MOUSE"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23455712", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19014335", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21947773", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21865384", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21424586", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16415166", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15937114", 
            "http://www.ncbi.nlm.nih.gov/pubmed/14500577", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12893884", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11356686", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7721348"
        ], 
        "id": "513832a75274a5fb07000012", 
        "ideal_answer": "Human IRG1 and mouse Irg1 mediates antiviral and antimicrobial immune responses, without its exact role having been elucidated. Irg1 has been suggested to have a role in apoptosis and to play a significant role in embryonic implantation. Irg1 is reported as the mammalian ortholog of methylcitrate dehydratase.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23455712", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 646, 
                "offsetInEndSection": 821, 
                "text": "we identified three interferon-stimulated genes (ISGs; Ifi27, Irg1 and Rsad2 (also known as Viperin)) that mediated the antiviral effects against different neurotropic viruses"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19014335", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1205, 
                "offsetInEndSection": 1440, 
                "text": "IRG1 is highly upregulated in murine ANA-1 macrophages by several proinflammatory cytokines and Toll-like receptor (TLR) agonists, as well as in spleen and lung of Listeria monocytogenes or Toxoplasma gondii infected mice, respectively"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19014335", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 78, 
                "text": "The proinflammatory cytokine-induced IRG1 protein associates with mitochondria"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947773", 
                "endSection": "title", 
                "offsetInBeginSection": 44, 
                "offsetInEndSection": 143, 
                "text": "multiple genes induced by Borrelia burgdorferi in macrophages to regulate Lyme disease inflammation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21865384", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 917, 
                "offsetInEndSection": 1164, 
                "text": "One of these genes, IRG1, was confirmed by single nucleotide polymorphism analysis to be involved in susceptibility. Its precise mechanism remains to be elucidated, although the analysis of gene expression data suggests it has a role in apoptosis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21424586", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 110, 
                "text": "Murine immune-responsive gene 1 (IRG1) plays significant roles in embryonic implantation and neurodegeneration"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21424586", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 638, 
                "offsetInEndSection": 732, 
                "text": "the IRG1 gene is differentially expressed in human fetal PBMCs and LPS-stimulated adult PBMCs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16415166", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 357, 
                "offsetInEndSection": 538, 
                "text": "we identified the immune-responsive gene 1 (IRG1), which was expressed substantially higher in lipopolysaccharide (LPS)-stimulated than in MAP-infected murine macrophage cell lines."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15937114", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 729, 
                "offsetInEndSection": 895, 
                "text": "The inhibitor also blocked induction by LIF of several LIF-regulated genes in the LE including Irg1, which has been shown previously to be essential for implantation."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14500577", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 127, 
                "text": "Immune-responsive gene 1 is a novel target of progesterone receptor and plays a critical role during implantation in the mouse."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14500577", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1510, 
                "offsetInEndSection": 1678, 
                "text": "our studies identified Irg1 as a novel target of PR in the pregnant uterus and also revealed that it is a critical regulator of the early events leading to implantation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893884", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 370, 
                "offsetInEndSection": 647, 
                "text": " This resulted in the identification of one novel P4-regulated gene that had been previously found in lipopolysaccharide-stimulated macrophages and called immune response gene-1 (Irg1) and which is the mammalian ortholog of the bacterial gene encoding methylcitrate dehydratase"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893884", 
                "endSection": "title", 
                "offsetInBeginSection": 27, 
                "offsetInEndSection": 103, 
                "text": "the mammalian ortholog of methylcitrate dehydratase (immune response gene 1)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11356686", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 358, 
                "offsetInEndSection": 474, 
                "text": "Here we report the isolation of a complementary DNA representing a novel gene, interferon-regulated gene 1 (IRG1). T"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11356686", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 358, 
                "offsetInEndSection": 637, 
                "text": "Here we report the isolation of a complementary DNA representing a novel gene, interferon-regulated gene 1 (IRG1). This gene exhibits significant homology to interferon (IFN)-alpha/beta-inducible human genes p27 and 6-16, indicating that these genes may belong to the same family"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11356686", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 975, 
                "offsetInEndSection": 1065, 
                "text": "The level of IRG1 mRNA again rose transiently on day 4 immediately preceding implantation."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11356686", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1678, 
                "offsetInEndSection": 1856, 
                "text": "Although the functional roles of IRG1 and p27 remain unclear, we describe for the first time, identification of a gene family regulated by IFNalpha in both rodent and human uteri"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7721348", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1615, 
                "offsetInEndSection": 1711, 
                "text": "Hence, the induction of IRG1 by LPS is mediated by tyrosine kinase and protein kinase C pathway."
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "Is thrombophilia related to increased risk of miscarriage?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019851", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018566", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011248", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011256", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011255", 
            "http://www.disease-ontology.org/api/metadata/DOID:10591", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0007565"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/22543699", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22164918", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21380983", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7986734", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15027582", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11583310", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19135285", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18845284", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16962918", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15713144", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19165673", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20860491"
        ], 
        "exact_answer": "Yes", 
        "id": "513cdc38bee46bd34c000007", 
        "ideal_answer": "Thrombophilia has been found to be considerably more common in women with pregnancy-associated complications in comparison with the general population, and most frequently in conjunction with venous thromboembolism during pregnancy and the postpartum period. In particular there is an increased risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. When counseling white women with a history of preeclampsia, screening for thrombophilia can be useful for preconceptional counseling and pregnancy management.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22543699", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1065, 
                "offsetInEndSection": 1159, 
                "text": "Thrombophilia does hardly increase the risk of IUGR/PMPC or if so, it can be prevented by LMWH"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164918", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 571, 
                "offsetInEndSection": 796, 
                "text": "for illustrative purposes, a patient presenting with combined thrombophilia--both genetic and acquired--will be discussed. This patient had suffered severe gestational complications that led to devastating obstetrical outcome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21380983", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 235, 
                "text": "Thrombophilias have been implicated in complications related to ischemic placental disease including recurrent pregnancy loss, intrauterine fetal demise, preeclampsia, fetal growth restriction, placental abruption, and preterm delivery"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7986734", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 905, 
                "offsetInEndSection": 1061, 
                "text": "Further information about the combined risk of aPC resistance and pregnancy is needed before guidance on the management of affected women can be formulated."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027582", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 148, 
                "offsetInEndSection": 263, 
                "text": "Thrombotic risk during pregnancy and the puerperium is higher in asymptomatic women with than without thrombophilia"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027582", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 734, 
                "offsetInEndSection": 870, 
                "text": "Further studies are required to assess the thrombotic risk in women with preeclampsia as well as early or late recurrent pregnancy loss."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583310", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 89, 
                "text": "Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583310", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1265, 
                "offsetInEndSection": 1532, 
                "text": "In conclusion, homozygous carriers of factor V Leiden and, to a lesser extent, double heterozygous carriers of factor V Leiden and of the prothrombin mutation have an increased risk of venous thrombosis during pregnancy, particularly high during the postpartum period"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19135285", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 767, 
                "offsetInEndSection": 873, 
                "text": "Careful diagnosis, observation and monitoring can add significant benefit to LMWH therapy during pregnancy"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 142, 
                "text": "Pregnancy in healthy women is accompanied by hypercoagulable changes that may interact with thrombophilia risk factors and threaten pregnancy."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1239, 
                "offsetInEndSection": 1444, 
                "text": "Fifty-three (13 %) women had antiphospholipid antibodies (lupus anticoagulant and/or anti-beta2-glycoprotein 1 antibodies) mainly associated with the risk of spontaneous abortion during the first trimester"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031171", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1461, 
                "offsetInEndSection": 1713, 
                "text": "thrombophilia was found to be considerably more common in women with pregnancy-associated complications in comparison with the general population, and most frequently in conjunction with venous thromboembolism during pregnancy and the postpartum period"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18845284", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1104, 
                "offsetInEndSection": 1262, 
                "text": "When counseling white women with a history of preeclampsia, screening for thrombophilia can be useful for preconceptional counseling and pregnancy management."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16962918", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 604, 
                "offsetInEndSection": 779, 
                "text": "knowledge combined with the appropriate use of thromboprophylaxis and treatment in women who have objectively confirmed VTE continue to improve maternal and perinatal outcomes"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15713144", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1508, 
                "offsetInEndSection": 1666, 
                "text": "The risk of having thrombophilia is doubled in men who have fathered pregnancies which ended in perinatal death as well as in the mothers of such pregnancies."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19165673", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 560, 
                "offsetInEndSection": 707, 
                "text": "The prevalence of thrombophilic variants is of possible public health significance for other morbidity; but perhaps not in relation to preeclampsia"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20860491", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 694, 
                "offsetInEndSection": 826, 
                "text": "This study suggests that thrombophilia \"mediates\" in lowering of cardiovascular risk factors in women with a history of preeclampsia"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Which extra thyroid tissues have thyrotropin (TSH) receptors?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011989", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004996", 
            "http://www.biosemantics.org/jochem#4250044"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/22517745", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22496347", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22399514", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22289392", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21956421"
        ], 
        "exact_answer": [
            [
                "adipose tissue"
            ], 
            [
                "fibrotic tissue"
            ]
        ], 
        "id": "513f45abbee46bd34c000013", 
        "ideal_answer": "TSH receptors are expressed also in extrathyroid tissues. TSH receptors seem to be functional. Extrathyroid tissues include fibrobasts of the orbit and adipose tissue\nThe principal tissues with TSH receptors are:\nadippose tissue\n orbital fibrotic tissue", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517745", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1217, 
                "offsetInEndSection": 1336, 
                "text": "GD orbital fibroblasts, which comprise a mixture of CD34(+) and CD34(-) cells, express much lower levels of Tg and TSHR"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517745", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 552, 
                "offsetInEndSection": 731, 
                "text": "Previously, we found that CD34(+) progenitor cells, known as fibrocytes, express functional TSHR, infiltrate the orbit, and comprise a large subset of orbital fibroblasts in TAO. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496347", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 882, 
                "offsetInEndSection": 923, 
                "text": "TSH induced lipolysis in adipose tissues."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496347", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1376, 
                "offsetInEndSection": 1434, 
                "text": "TSH worked as a lipolytic factor in white adipose tissues,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 303, 
                "offsetInEndSection": 439, 
                "text": "These fibrocytes infiltrate orbital connective tissues in thyroid-associated ophthalmopathy and express functional TSH receptor (TSHR). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21956421", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1047, 
                "offsetInEndSection": 1104, 
                "text": "TSHR levels are higher than those in orbital fibroblasts."
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "What is the methyl donor of DNA (cytosine-5)-methyltransferases?", 
        "concepts": [
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003886", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019175"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/8441638", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11208790", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7607467", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8065896", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7578083", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1584813", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15273274"
        ], 
        "exact_answer": [
            "S-adenosyl-L-methionine"
        ], 
        "id": "51404dd723fec90375000002", 
        "ideal_answer": "S-adenosyl-L-methionine (AdoMet, SAM) is the methyl donor of DNA (cytosine-5)-methyltransferases. DNA (cytosine-5)-methyltransferases catalyze the transfer of a methyl group from S-adenosyl-L-methionine to the C-5 position of cytosine residues in DNA.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8441638", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 256, 
                "text": "The product of the dcm gene is the only DNA cytosine-C5 methyltransferase of Escherichia coli K-12; it catalyses transfer of a methyl group from S-adenosyl methionine (SAM) to the C-5 position of the inner cytosine residue of the cognate sequence CCA/TGG. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11208790", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 284, 
                "text": "Deoxycytosine methylase (Dcm) enzyme activity causes mutagenesis in vitro either directly by enzyme-induced deamination of cytosine to uracil in the absence of the methyl donor, S-adenosylmethionine (SAM), or indirectly through spontaneous deamination of [5-methyl]cytosine to thymine"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7607467", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 218, 
                "text": "In the absence of DNA substrate, the DNA methyltransferase (MTase) M.BspRI can methylate itself using the methyl donor S-adenosyl-L-methionine (AdoMet). The methyl group is transferred to two Cys residues of the MTase."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7578083", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 446, 
                "offsetInEndSection": 539, 
                "text": "The reaction is fairly insensitive to the methyl donor in the reaction, S-adenosylmethionine."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1584813", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 641, 
                "offsetInEndSection": 831, 
                "text": "Formation of the complex was dependent upon the presence of the methyl donor S-adenosylmethionine, suggesting that it comprises an enzyme-linked 5-substituted dihydrocytosine moiety in DNA. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8065896", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 264, 
                "text": "The DNA (cytosine-5)-methyltransferase (m5C-MTase) M.BspRI is able to accept the methyl group from the methyl donor S-adenosyl-L-methionine (AdoMet) in the absence of DNA. Transfer of the methyl group to the enzyme is a slow reaction relative to DNA methylation. S"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15273274", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 170, 
                "offsetInEndSection": 374, 
                "text": "Here, we report the structure of HhaI methyltransferase in complex with DNA containing a south-constrained abasic carbocyclic sugar at the target site in the presence of the methyl donor byproduct AdoHcy."
            }
        ], 
        "type": "factoid"
    }, 
    {
        "body": "Super-SILAC is a method used in quantitative proteomics. What is the super-SILAC mix?\n(SILAC: Stable Isotopic labelling by aminoacids in cell culture)", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007553"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23090970", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22623409", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22442255", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22278370", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21293456", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20431548", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20364148"
        ], 
        "id": "51430930d24251bc0500000b", 
        "ideal_answer": "The Super-SILAC mix consists of the combination of multiple SILAC-labeled cell lines.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21293456", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1289, 
                "offsetInEndSection": 1371, 
                "text": ", a mixture of five SILAC-labeled cell lines that accurately represents the tissue"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20364148", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 208, 
                "text": "We describe a method to accurately quantify human tumor proteomes by combining a mixture of five stable-isotope labeling by amino acids in cell culture (SILAC)-labeled cell lines with human carcinoma tissue. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442255", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 965, 
                "offsetInEndSection": 1074, 
                "text": "the use of a mix of multiple SILAC-labeled cell lines as an internal standard, a technique called super-SILAC"
            }, 
            {
                "beginSection": "sections.4", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442255", 
                "endSection": "sections.4", 
                "offsetInBeginSection": 1149, 
                "offsetInEndSection": 1226, 
                "text": "Equal amounts of the heavy lysates were mixed to generate the super-SILAC mix"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090970", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 441, 
                "offsetInEndSection": 599, 
                "text": "For accurate quantification we developed a super-SILAC mix from several labeled breast cancer cell lines and used it as an internal standard for all samples. "
            }, 
            {
                "beginSection": "sections.4", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22278370", 
                "endSection": "sections.4", 
                "offsetInBeginSection": 1010, 
                "offsetInEndSection": 1171, 
                "text": "For the preparation of super-SILAC mix (18) equal amounts of heavy lysates were mixed and then combined with nonlabeled cells as described in the RESULTS section"
            }, 
            {
                "beginSection": "sections.5", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22278370", 
                "endSection": "sections.5", 
                "offsetInBeginSection": 20616, 
                "offsetInEndSection": 21220, 
                "text": "to select five cell lines, chosen to be as dissimilar to each other as possible (Jurkat, HEK293, LnCap, HeLa, and K562).As expected from the high correlations, even the SILAC quantification experiments between binary combinations of heavy and light labeled cell lines resulted in narrow ratio distributions (Fig. 6A, 6B). This was further improved in the quantification of the heavy super-SILAC mix against a single cell line (Fig. 6C). These experiments also suggest a general strategy to construct super-SILAC mixes and to evaluate their suitability for quantifying any cell line (or tissue) of interes"
            }, 
            {
                "beginSection": "sections.5", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22278370", 
                "endSection": "sections.5", 
                "offsetInBeginSection": 21465, 
                "offsetInEndSection": 21609, 
                "text": " Knowledge of the overall similarities of the proteomes was used to construct a five cell line, heavy labeled \u201csuper-SILAC\u201d reference standard. "
            }, 
            {
                "beginSection": "sections.5", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442255", 
                "endSection": "sections.5", 
                "offsetInBeginSection": 22657, 
                "offsetInEndSection": 22790, 
                "text": "We developed and used a super-SILAC mix of labeled B-cell lymphoma cell lines as an internal standard to segregate subtypes of DLBCL."
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "Tumors of which three organs are classically associated with the multiple endocrine neoplasia type 1 syndrome?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018761", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23279763", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23024266", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21613051", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21302639", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18172277", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17455252", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11914929", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10664520", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9820618", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9735087", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9236523", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7962349"
        ], 
        "exact_answer": [
            [
                "parathyroid gland"
            ], 
            [
                "pancreas"
            ], 
            [
                "pituitary gland"
            ]
        ], 
        "id": "51477de5d24251bc05000020", 
        "ideal_answer": "Multiple endocrine neoplasia type 1 syndrome is an inherited cancer syndrome defined by occurrence of multiple neuro-endocrine tumors and is classically associated with the combined occurrence of two or more tumors involving parathyroid gland, pancreas and pituitary gland. Other tumors, including but not limited to adrenal cortical tumor, carcinoid tumors lipoma, leiomyoma, duodenal gastrinoma, hepatic focal nodular hyperplasia, and renal angiomyolipoma, angiofibroma, colagenoma, thyroid tumor and meningioma, may also be present.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 275, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1; formerly known as Wermer syndrome) is a rare disorder characterized by the combined occurrence of two or more tumors involving parathyroid, pancreatic islets and anterior pituitary glands; some other tumors have also been described."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 950, 
                "offsetInEndSection": 1154, 
                "text": " Hyperparathyroidism is the most common feature of MEN1 (95% of patients), pancreatic islet tumors or pancreatic NET (neuroendocrine tumor) occur in 40-70% and pituitary tumors in 30-40% of MEN 1 patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1155, 
                "offsetInEndSection": 1302, 
                "text": " In addition, other tumors, such as adrenal cortical tumors, carcinoid tumors, lipomas, angiofibromas, colagenomas and meningiomas may be present. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435440", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1705, 
                "offsetInEndSection": 1803, 
                "text": "the most important causes malignant pancreatic neuroendocrine tumors (NET) and thymic carcinoids. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23279763", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 292, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is inherited in an autosomal dominant fashion and predisposes to the development of hyperplastic or neoplastic changes in the parathyroid and pituitary glands and the endocrine pancreas, along with numerous other characteristic tumors and features. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024266", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 224, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the combined occurrence of parathyroid and adrenocortical tumors, and neuroendocrine tumors (NETs) of the pancreas and pituitary. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23024266", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 224, 
                "offsetInEndSection": 362, 
                "text": "The pancreatic NETs are predominantly gastrinomas and insulinomas, and the pituitary NETs are mostly prolactinomas and somatotrophinomas. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613051", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 461, 
                "offsetInEndSection": 617, 
                "text": "We address the potential role of miRNAs in the endocrine pancreas, the pituitary gland, and the parathyroid glands-areas where MEN 1 shows high penetrance. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613051", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 749, 
                "offsetInEndSection": 921, 
                "text": "Moreover, studies have provided evidence that dysregulation of miRNAs was responsible for endocrine carcinogenesis, including pancreatic, pituitary, and parathyroid tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302639", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 111, 
                "text": "MEN1 and MEN2 are rare inherited cancer syndromes which express a variety of endocrine and nonendocrine tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 141, 
                "text": "Multiple endocrine neoplasia Type 1 (MEN1) is a rare hereditary tumor syndrome predisposing to tumor development in several endocrine organs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 141, 
                "offsetInEndSection": 240, 
                "text": " Its major manifestations include hyperparathyroidism, tumors of endocrine pancreas and pituitary. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 241, 
                "offsetInEndSection": 459, 
                "text": "eside these three, several other endocrine (adrenocortical, foregut carcinoid) and nonendocrine (lipoma, angiofibroma, collagenoma, ependymoma, meningioma) tumors have been described to be associated with this syndrome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 461, 
                "offsetInEndSection": 764, 
                "text": "Both familial and sporadic forms of the disease are known. The diagnosis of MEN1 can be established if two of the three major manifestations are found in the same patient, whereas the diagnosis of familial MEN1 requires one MEN1 patient and a first degree relative with at least one MEN1 manifestation. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 875, 
                "offsetInEndSection": 997, 
                "text": "Both benign (parathyroid, anterior pituitary) and malignant (gastrinoma, glucagonoma) lesions may develop in MEN1 patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11914929", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 203, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is a classic hereditary tumor syndrome characterized by a genetic predisposition to develop a variety of neuroendocrine neoplasias and hormone excess syndromes."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10664520", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 136, 
                "text": "Multiple endocrine neoplasia type 1 (MEN 1) is a familial syndrome characterized by parathyroid, enteropancreatic and pituitary tumors. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9820618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 154, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome characterized by the development of multiple endocrine tumors"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9236523", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 698, 
                "offsetInEndSection": 1175, 
                "text": "Multiple facial angiofibromas were observed in 28 (88%) of the patients with MEN1, with 16 patients (50%) having 5 or more. Angiofibromas were clinically and histologically identical to those in individuals with tuberous sclerosis. Collagenomas were observed in 23 patients (72%). Also observed were cafe au lait macules in 12 patients (38%), lipomas in 11 patients (34%), confetti-like hypopigmented macules in 2 patients (6%), and multiple gingival papules in 2 patients (6%)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9236523", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1190, 
                "offsetInEndSection": 1484, 
                "text": "Multiple angiofibromas, collagenomas, lipomas, confetti-like hypopigmented macules and multiple gingival papules are cutaneous manifestations of MEN1 and should be looked for in both family members of patients with MEN1 and individuals with hyperparathyroidism of other MEN1-associated tumors. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962349", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 266, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder characterized by nodular proliferation of the parathyroid glands and tumors of the anterior pituitary gland, the endocrine pancreas, and the neuroendocrine cell system of the gut."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7962349", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 400, 
                "offsetInEndSection": 613, 
                "text": "We report here a genetic study of a female MEN1 patient with the association of nodular hyperplasia of two parathyroid glands, an insulinoma, multiple duodenal gastrinomas, a prolactinoma, and a gastric carcinoid."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18172277", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 213, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is defined clinically by the combined occurrence of multiple tumors, typically of the parathyroid glands, pancreatic islet cells, and anterior pituitary gland."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17455252", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1125, 
                "offsetInEndSection": 1485, 
                "text": "In support of previous findings in islet tumors, we found down-regulation of the cell-cycle regulator, p18, in both the pancreatic islet and pituitary adenomas, suggesting that reduced p18 levels may be important for Men1-related tumorigenesis in multiple tissues. Surprisingly, we identified increased p16 transcript in pancreatic islet and pituitary tumors. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 163, 
                "offsetInEndSection": 458, 
                "text": " The patient was studied and diagnosed with a multiple endocrine neoplasia type I (MEN I), familiar (mother with MEN I). A scintigraphic study with 99mTc-MIBI was performed in order to localize hyperfunctioning parathyroid glands because of biochemical diagnosis of primary hyperparathyroidism. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 761, 
                "offsetInEndSection": 869, 
                "text": "The tumor was removed and histologically confirmed as a carcinoid within a thymus in a MEN type I syndrome. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10614532", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 869, 
                "offsetInEndSection": 1040, 
                "text": "MEN I patients can benefit from the examination with this agent which can potentially localize not only parathyroid endocrine pathology but also unknown associated tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 149, 
                "text": "Pancreatic endocrine tumors occur sporadically and as part of the multiple endocrine neoplasia type 1 (MEN 1) and von Hippel-Lindau (VHL) syndromes. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 436, 
                "offsetInEndSection": 701, 
                "text": "We have analyzed 22 nonfamilial and 16 MEN 1-associated pancreatic endocrine tumors for loss of heterozygosity (LOH) at 3p, 11q13, and 18q. LOH at 3p was revealed in 45% and 36% of tumors from 31 patients with nonfamilial and MEN 1-associated disease, respectively."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502325", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1470, 
                "offsetInEndSection": 1670, 
                "text": "The data indicate involvement of tumor suppressor genes on 3p and 18q, in addition to the MEN1 gene at 11q13, in the tumorigenesis of both nonfamilial and MEN 1-associated pancreatic endocrine tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 282, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) is characterized by the development of endocrine tumors of the parathyroid and pituitary glands, pancreas, and duodenum. Less frequently occurring tumors associated with MEN1 include non-endocrine tumors such as lipomas and angiofibromas. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 282, 
                "offsetInEndSection": 468, 
                "text": "An increased incidence of thyroid neoplasms, leiomyomas, adrenal cortical hyperplasia, hepatic focal nodular hyperplasia, and renal angiomyolipoma has been noted in the MEN1 population. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 1055, 
                "text": "A germline mutation of the MEN1 gene was detected, and deletions of the MEN1 gene were consistently detected in multiple neuroendocrine tumors involving the parathyroid glands and the pancreas and a hepatic neuroendocrine tumor metastasis, as predicted by Knudson's \"two hit\" hypothesis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1071, 
                "offsetInEndSection": 1232, 
                "text": "Two hits of the MEN1 gene were also detected in esophageal leiomyoma tissue, suggesting that tumorigenesis was directly related to the patient's underlying MEN1."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10496602", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1237, 
                "offsetInEndSection": 1612, 
                "text": " In contrast, follicular thyroid adenoma, papillary thyroid carcinoma, hepatic focal nodular hyperplasia, and adrenal cortical hyperplasia consistently showed retained heterozygosity of the MEN1 gene with flanking markers and an intragenic marker. Therefore, these tumors appear to develop along pathogenetic pathways that are different from classical MEN1-associated tumors."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9820618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 312, 
                "offsetInEndSection": 624, 
                "text": "Twelve unrelated (German MEN1 families and their associated tumors (5 parathyroid tumors, 1 vipoma, 1 gastrinoma, 1 insulinoma) were characterized for MEN1 gene mutations by single-strand conformational variant (SSCV) analysis and DNA sequence analysis as well as for loss of heterozygosity on chromosome 11q13. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9735087", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 277, 
                "text": "Multiple endocrine neoplasia type 1 (MEN1) consists of benign, and sometimes malignant, tumors (often multiple in a tissue) of the parathyroids, enteropancreatic neuroendocrine system, anterior pituitary, and other tissues. Skin angiofibromas and skin collagenomas are common. "
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "What is the mechanism of action of anticoagulant medication Dabigatran?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504", 
            "http://www.biosemantics.org/jochem#4242811"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23466964", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23031622", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22480286", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22388002", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21988948", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21666370", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21526168", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20888031", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20589316", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19888525", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18425569", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16637459"
        ], 
        "id": "51485a4dd24251bc0500002a", 
        "ideal_answer": "Dabigatran is orally administered, reverisble direct and competetive inhibitor of both free and bouded thrombin.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23031622", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 161, 
                "offsetInEndSection": 313, 
                "text": "Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480286", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 455, 
                "offsetInEndSection": 584, 
                "text": "Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21988948", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 423, 
                "offsetInEndSection": 716, 
                "text": "The recently introduced oral direct thrombin antagonist, dabigatran, has been shown in phase III clinical trials to be noninferior in efficacy to warfarin for the prevention of thromboembolic events in patients with atrial fibrillation, as well as in treatment of acute venous thromboembolism."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21666370", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 465, 
                "offsetInEndSection": 669, 
                "text": "Dabigatran is an oral, reversible direct thrombin inhibitor approved in Europe and in several other countries for the prevention of venous thromboembolism after elective knee and hip replacement surgery. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21526168", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1029, 
                "offsetInEndSection": 1347, 
                "text": "This mechanism of action is different from that of other anticoagulants that have been or are currently used in clinical practice, such as warfarin (a vitamin K antagonist) [4], enoxaparin (an indirect thrombin/Factor Xa inhibitor) [5], [6], ximelagatran (now withdrawn) [7] and dabigatran (direct thrombin inhibitors)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20888031", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 886, 
                "offsetInEndSection": 988, 
                "text": "Dabigatran etexilate is a direct thrombin inhibitor that inhibits both free and fibrin-bound thrombin."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20589316", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 249, 
                "offsetInEndSection": 395, 
                "text": "Direct inhibitors of FXa (rivaroxaban), FVIIa (BMS-593214), thrombin (dabigatran, argatroban) and FXIa (BMS-262084) were included for comparison. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888525", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 958, 
                "offsetInEndSection": 1196, 
                "text": "Two agents, the direct thrombin inhibitor dabigatran and the direct Factor Xa inhibitor rivaroxaban, have recently been approved in the EU and several other countries for the prevention of VTE after total hip or knee replacement surgery. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18425569", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 702, 
                "offsetInEndSection": 776, 
                "text": "The direct thrombin inhibitor dabigatran is farthest along in development."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16637459", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1742, 
                "offsetInEndSection": 1950, 
                "text": "Lastly, inhibitors of thrombin activity are composed of either indirect (UFH, LMWH), or direct thrombin (FIIa) inhibitors including: hirudin, argatroban, melagatran, ximelagatran, dabigatran, and bivalirudin."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466964", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 334, 
                "text": "The effect of the oral direct activated factor X (factor Xa) inhibitor apixaban on tissue factor-induced thrombin generation in human plasma was investigated in vitro using the calibrated automated thrombogram (CAT) method and compared with the oral direct factor Xa inhibitor rivaroxaban and the direct thrombin inhibitor dabigatran."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22388002", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 538, 
                "offsetInEndSection": 780, 
                "text": "The DTI dabigatran etexilate was recently shown to provide superior risk reduction to warfarin for stroke and systemic embolism for patients with nonvalvular AF and recently gained US Food and Drug Administration approval for this indication."
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "Is Mammaprint approved by the United States Food and Drug Administration?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017321", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017322", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017326", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017327"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19879448", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19546609", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18515733", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17462970"
        ], 
        "exact_answer": "Yes", 
        "id": "51487821d24251bc0500002f", 
        "ideal_answer": "Yes, Mammaprint has been approved by the US Food and Drug Administration.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1432, 
                "offsetInEndSection": 1485, 
                "text": "an FDA-cleared 70-gene signature of MammaPrint panel "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19879448", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 460, 
                "offsetInEndSection": 562, 
                "text": "on MammaPrint, the first and only assay for breast cancer management that has been cleared by the FDA."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546609", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1614, 
                "offsetInEndSection": 1862, 
                "text": "The MammaPrint assay has the advantages of a 510(k) clearance by the US Food and Drug Administration, a larger gene number which may enhance further utility, and the potentially wider patient eligibility including lymph node-positive, ER-negative, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1806, 
                "offsetInEndSection": 1909, 
                "text": "MammaPrint from Agendia are the first FDA approved microarray-based tests for diagnostic applications. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506735", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 2899, 
                "offsetInEndSection": 3099, 
                "text": "MammaPrint is the first FDA approved, gene expression-based prognostic test which assess patients\u2019 risk for distant metastasis in women under age 61 with Stage I-II lymph node negative breast cancer. "
            }, 
            {
                "beginSection": "sections.3", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786252", 
                "endSection": "sections.3", 
                "offsetInBeginSection": 4677, 
                "offsetInEndSection": 4869, 
                "text": "The Amsterdam 70-gene expression signature as breast cancer prognosis marker has been validated in follow-up studies [39,40], and a clinical assay MammaPrint\u00ae has recently been cleared by FDA."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18515733", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1391, 
                "offsetInEndSection": 1785, 
                "text": "The MammaPrint assay has the advantages of a 510(k) clearance by the U.S. Food and Drug Administration, a larger gene number, which may enhance further utility, and a potentially wider patient eligibility, including lymph node-positive, estrogen receptor (ER)-negative, and younger patients being accrued into the prospective trial (Microarray in Node-Negative Disease May Avoid Chemotherapy). "
            }
        ], 
        "triples": [
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A17680439", 
                "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
                "s": "http://linkedlifedata.com/resource/umls/id/C2827401"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_4434464B59390011"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_51395844503300D"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_4F383737393600D"
            }, 
            {
                "o": "fda", 
                "p": "http://www.w3.org/2004/02/skos/core#altLabel", 
                "s": "http://linkedlifedata.com/resource/#_4530503539300011"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009157", 
            "http://www.disease-ontology.org/api/metadata/DOID:437", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002800", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000110", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21328290", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21133188", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15610702", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21845054"
        ], 
        "exact_answer": [
            [
                "neostigmine"
            ], 
            [
                "pyridostigmine"
            ]
        ], 
        "id": "5149199dd24251bc05000040", 
        "ideal_answer": "Pyridostigmine and neostygmine are acetylcholinesterase inhibitors that are used as first-line therapy for symptomatic treatment of myasthenia gravis. Pyridostigmine is the most widely used acetylcholinesterase inhibitor. Extended release pyridotsygmine and novel acetylcholinesterase inhibitors inhibitors with oral antisense oligonucleotides are being studied.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21133188", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1251, 
                "offsetInEndSection": 1321, 
                "text": "Pyridostigmine is the most widely used acetylcholinesterase inhibitor."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 171, 
                "text": "For more than 50 years the acetylcholinesterase inhibitor pyridostigmine bromide has been the drug of choice in the symptomatic therapy for myasthenia gravis. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 871, 
                "offsetInEndSection": 1229, 
                "text": "The switch to SR-Pyr ameliorated the total quantified myasthenia gravis (QMG) score from 0.9 \u00b1 0.5 to 0.6 \u00b1 0.4 (p<0.001) in all patients and in the younger subgroup. This was accompanied by a significant improvement in the quality of life parameters. The health status valued by EuroQoL questionnaire improved from 0.626 \u00b1 0.286 to 0.782 \u00b1 0.186 (p<0.001). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663605", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1412, 
                "offsetInEndSection": 1578, 
                "text": "Our results support the usefulness of SR-Pyr in an individualized therapeutic regimen to improve quality of life regardless of the patient's age in myasthenia gravis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 476, 
                "offsetInEndSection": 571, 
                "text": "This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 572, 
                "offsetInEndSection": 768, 
                "text": "Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1071, 
                "offsetInEndSection": 1197, 
                "text": "Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21328290", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2418, 
                "offsetInEndSection": 2808, 
                "text": "Except for one small and inconclusive trial of intranasal neostigmine, no randomised controlled trial has been conducted on the use of acetylcholinesterase inhibitors in myasthenia gravis. Response to acetylcholinesterase inhibitors in observational studies is so clear that a randomised controlled trial depriving participants in the placebo arm of treatment would be difficult to justify."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 178, 
                "offsetInEndSection": 475, 
                "text": " Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21815707", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 1071, 
                "text": "Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610702", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 343, 
                "offsetInEndSection": 452, 
                "text": "Acetylcholinesterase inhibitors provide temporary, symptomatic treatment for all forms of myasthenia gravis. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21845054", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 52, 
                "offsetInEndSection": 340, 
                "text": "In MG, the first-line option is symptomatic treatment with acetylcholinesterase inhibitors. Pyridostigmine bromide is the most commonly used drug. Other acetylcholinesterase inhibitors such as neostigmine are rarely used because of their poorer pharmacodynamic profiles and tolerability. "
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21845054", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 339, 
                "offsetInEndSection": 659, 
                "text": " In an observational study of 14 MG patients comparing pyridostigmine with neostigmine, it was concluded that over 1 year, pyridostigmine was more effective with less adverse events.5 Similar conclusions were reached in another observational study of 69 patients which compared the use of pyridostigmine with neostigmine"
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "Which medication should be administered when managing patients with suspected acute opioid overdose?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000701", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009292", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062787"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17849242", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11130352", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11015242", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8907145", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1470965"
        ], 
        "exact_answer": [
            "naloxone"
        ], 
        "id": "5149f494d24251bc0500004c", 
        "ideal_answer": "Naloxone is opioid anagonist that should be administered for all patients with suspected acute opioid overdose. Intravenous naltrexone hydrochloride is usually administered, however, other formulations, including enteral methylnaltrexone, nebulized naloxone and subcutaneous naloxone, are under investigation and can be used under certain circumstances.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 145, 
                "text": "Opioid overdose has a high mortality, but is often reversible with appropriate overdose management and naloxone (opioid antagonist). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1691, 
                "offsetInEndSection": 1782, 
                "text": "Training clinicians how to manage an opioid overdose and administer naloxone was effective."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849242", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2841, 
                "offsetInEndSection": 3085, 
                "text": "For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 200, 
                "offsetInEndSection": 394, 
                "text": "Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11130352", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 394, 
                "offsetInEndSection": 567, 
                "text": "Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11015242", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 184, 
                "offsetInEndSection": 336, 
                "text": "Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11015242", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 741, 
                "offsetInEndSection": 843, 
                "text": "Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 202, 
                "text": "To determine whether naloxone administered i.v. to out-of-hospital patients with suspected opioid overdose would have a more rapid therapeutic onset than naloxone given subcutaneously (s.q.)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 540, 
                "offsetInEndSection": 677, 
                "text": "Subjects received either naloxone 0.4 mg i.v. (n = 74) or naloxone 0.8 mg s.q. (n = 122), for respiratory depression of <10 breaths/min. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9562190", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1143, 
                "offsetInEndSection": 1371, 
                "text": "There was no clinical difference in the time interval to respiratory rate > or =10 breaths/min between naloxone 0.8 mg s.q. and naloxone 0.4 mg i.v. for the out-of-hospital management of patients with suspected opioid overdose. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8907145", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 243, 
                "offsetInEndSection": 518, 
                "text": "To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1470965", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1150, 
                "offsetInEndSection": 1360, 
                "text": "Management of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid overdose, whether illicit or iatrogenic, requires the prompt and skillful use of opioid antagonists. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044832", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1431, 
                "offsetInEndSection": 1677, 
                "text": " The proportion of clinicians willing to use naloxone in an opioid overdose rose from 77% to 99% after training. Barriers to implementing training were clinician time and confidence, service resources, client willingness and naloxone formulation."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8907145", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 243, 
                "text": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. "
            }
        ], 
        "type": "factoid"
    }, 
    {
        "body": "Does the Oncotype DX test work with paraffin embedded tissues?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016612"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17140367", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16361546"
        ], 
        "exact_answer": "Yes", 
        "id": "514a0f0ad24251bc05000052", 
        "ideal_answer": "Yes, the Oncotype DX test works with paraffin embedded tissue.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074401", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2732, 
                "offsetInEndSection": 3135, 
                "text": "The Oncotype-DX Breast Cancer Assay (Genomic Health, Redwood City, CA) quantifies gene expression for 21 genes in breast cancer tissue by performing reverse transcription polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded (FFPE) tumour blocks that are obtained during initial surgery (lumpectomy, mastectomy, or core biopsy) of women with early breast cancer that is newly diagnosed."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922117", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 211, 
                "offsetInEndSection": 546, 
                "text": "Oncotype DXtrade mark, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 250, 
                "text": "Oncotype DX is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 512, 
                "offsetInEndSection": 578, 
                "text": "We therefore investigated the analytical performance of the assay."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463177", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 588, 
                "offsetInEndSection": 848, 
                "text": "Assays used a pooled RNA sample from fixed paraffin-embedded tissues to evaluate the analytical performance of a 21-gene panel with respect to amplification efficiency, precision, linearity, and dynamic range, as well as limits of detection and quantification."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17140367", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 726, 
                "offsetInEndSection": 960, 
                "text": "One such strategy is the 21-gene assay (Oncotype DX), which is currently in commercial use in the USA. One advantage of this test is the use of paraffin-embedded blocks instead of previous methods, which required fresh frozen tissue. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 119, 
                "offsetInEndSection": 263, 
                "text": "We used paraffin-embedded core biopsies from a completed phase II trial to identify genes that correlate with response to primary chemotherapy. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17039265", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 590, 
                "offsetInEndSection": 700, 
                "text": "In addition to the individual genes, the correlation of the Oncotype DX Recurrence Score with pCR was examined"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361546", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 377, 
                "offsetInEndSection": 415, 
                "text": "RNA was extracted from paraffin blocks"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16361546", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 55, 
                "offsetInEndSection": 114, 
                "text": "to develop the 21-gene Recurrence Score assay (Oncotype DX)"
            }
        ], 
        "triples": [
            {
                "o": "Paraffin", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A7572812"
            }, 
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A9424108", 
                "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
                "s": "http://linkedlifedata.com/resource/umls/id/C0030415"
            }, 
            {
                "o": "Paraffin", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A17999423"
            }, 
            {
                "o": "PARAFFIN", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A8438050"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A16755941"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Is depression associated with poor prognosis of brain tumor patients?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001932", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011379", 
            "http://www.disease-ontology.org/api/metadata/DOID:1319", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016019", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017063"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/16304988", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16960653", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15072475"
        ], 
        "exact_answer": "yes", 
        "id": "514cc8dcd24251bc05000066", 
        "ideal_answer": "Yes. In brain tumor patients depression is associated with shorter survival and worse functional outcomes.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304988", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 583, 
                "offsetInEndSection": 820, 
                "text": "Before surgery 27 patients (35%) had BDI scores indicating the presence of depression. These scores were significantly higher in patients with a history of depression (p = 0.017) and in those with a lower functional outcome (p = 0.015). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304988", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 949, 
                "offsetInEndSection": 1129, 
                "text": "A lower functional status (KPS score < or = 70) in patients was significantly associated with high depression scores at the 3-month (p = 0.000) and 1-year (p = 0.005) assessments. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960653", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 782, 
                "offsetInEndSection": 965, 
                "text": "At all follow-ups, depressed low-grade glioma patients had a significantly shorter survival time, 3.3-5.8 years, compared to non-depressed low-grade glioma patients, 10.0-11.7 years. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960653", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1083, 
                "offsetInEndSection": 1224, 
                "text": "The results suggest that depression and decreased QOL among low-grade glioma patients is related to shorter survival at long-term follow-up. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 144, 
                "text": "The adverse impact of depression in relation to survival among cancer patients is currently a subject of great interest in research. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1192, 
                "offsetInEndSection": 1388, 
                "text": " In the subgroup of patients with low-grade gliomas, depressive patients had a significantly shorter survival time compared with nondepressive subjects (P = 0.031, Kaplan-Meier survival analysis)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15918939", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1731, 
                "offsetInEndSection": 1848, 
                "text": "Preoperative depression seemed to be a significant prognostic factor for worse survival in low-grade glioma patients."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15072475", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1075, 
                "offsetInEndSection": 1245, 
                "text": "Major depressive disorder was marginally associated with outcomes, while surgical interventions and radiotherapy did not show strong associations with test performances. "
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "What is known about the reimbursement of Viagra", 
        "concepts": [
            "http://www.biosemantics.org/jochem#4266960", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012051", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007349", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012052", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007348", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009313", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007341", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006278", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009310", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008329", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007356", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007350", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012943", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019458", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007342", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007357", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059033", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059034", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003365", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007345", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017281", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016527", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017048"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/19715380", 
            "http://www.ncbi.nlm.nih.gov/pubmed/14769012", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12442853", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12119585", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10858175", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10718038", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
            "http://www.ncbi.nlm.nih.gov/pubmed/14769010", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23231890", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22554140", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20608882", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16194131", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10345973"
        ], 
        "id": "5150b45ad24251bc0500006f", 
        "ideal_answer": "Coverage of Viagra/Sildenafil for erectile dysfunction by health insurance plans is a contentious issue in developed countries. There are data of the limitations (6 per month) and co-payments (26.6%) by patients  in the US.\nThe costs for Viagra/Sildenafil for PAH (pulmonary artery hypertension) appear to be covered by health insurances in the US.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715380", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 887, 
                "offsetInEndSection": 1031, 
                "text": "Treatment with sildenafil was less costly and resulted in a greater gain in quality-adjusted life-years (QALYs) compared with other treatments. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19715380", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1214, 
                "offsetInEndSection": 1329, 
                "text": "Based on this model, sildenafil is a cost-effective treatment for PAH with a low price and a net increase in QALYs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14769012", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 713, 
                "offsetInEndSection": 917, 
                "text": "Four treatment strategies, Viagra, Rivastigmine, statins, and lung transplants, are analysed with respect to whether either cost-effectiveness or need, or both, seem to have played a role in the decisions"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14769012", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1154, 
                "offsetInEndSection": 1246, 
                "text": "it seems that decisions are almost exclusively made with reference to the principle of need."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14769012", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 128, 
                "offsetInEndSection": 138, 
                "text": "In Sweden "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14769012", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1324, 
                "offsetInEndSection": 1563, 
                "text": "decisions on priority setting are almost solely based on the principle of need. This implies that the principle of cost-effectiveness is given very little space, which is a problem as this means an obvious risk of inefficient resource use."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12442853", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 530, 
                "offsetInEndSection": 721, 
                "text": "The case of Viagra, it concludes, holds out two general lessons: first, allow exceptions to total bans on reimbursement; second, involve the medical profession in the decision-making process."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12442853", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 260, 
                "offsetInEndSection": 377, 
                "text": "This paper analyzes the rationing strategies adopted in four countries (United States, Britain, Germany, and Sweden),"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12119585", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 44, 
                "offsetInEndSection": 178, 
                "text": "the question whether statutory social health insurances are obliged to reimburse the costs for the treatment of erectile dysfunction. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10858175", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 85, 
                "text": "Coverage of sildenafil by health insurance plans is a contentious issue. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10718038", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 725, 
                "offsetInEndSection": 983, 
                "text": "coverage of Viagra and Zyban was limited predominantly through generalized exclusion or through restrictions on quantity or duration of use. Value judgments, rather than cost, seem to play a central, though largely unspoken, role in these coverage decisions."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 284, 
                "offsetInEndSection": 486, 
                "text": "availability of orphan drugs and in patient access to them in 11 pharmaceutical markets: Australia, Canada, England, France, Germany, Hungary, the Netherlands, Poland, Slovakia, Switzerland and the US. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073206", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2412, 
                "offsetInEndSection": 2816, 
                "text": "lthough the present study showed some variations between countries in selected indicators of availability and access to orphan drugs, virtually all of the drugs in question were available and accessible in our sample. However, substantial co-payments in the US and Canada represent important barriers to patient access, especially in the case of expensive treatments such as those analysed in this study."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231890", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 189, 
                "offsetInEndSection": 383, 
                "text": "Using a large US health insurance claims database, we identified all patients with evidence of PAH (ICD-9-CM diagnosis codes 416.0, 416.8) who received sildenafil between 1/1/2005 and 9/30/2008."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231890", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1256, 
                "offsetInEndSection": 1655, 
                "text": "The mean cost of all PAH-related medication was $7139 during pretreatment and $14,095 during follow-up (sildenafil cost during follow-up=\u2009$5236); exclusive of PAH-related medications, however, total healthcare costs decreased modestly (from $30,104 to $27,605) (p<0.01 for all comparisons). CONCLUSIONS: The cost of sildenafil therapy may be partially offset by reductions in other healthcare costs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22554140", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 223, 
                "offsetInEndSection": 370, 
                "text": "Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicare Advantage) through 30 June 2008 were identified."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22554140", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1141, 
                "offsetInEndSection": 1236, 
                "text": "Most patients (94%) initiated treatment with monotherapy (most commonly sildenafil or bosentan)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22554140", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1659, 
                "offsetInEndSection": 1761, 
                "text": "Mean PAH-related healthcare costs were $6617 per patient per month, comprising 71% of all-cause costs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20608882", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 141, 
                "offsetInEndSection": 278, 
                "text": "Retrospective claims database analysis of 706 patients with PAH enrolled in a large, geographically diverse US managed-care organization."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20608882", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1816, 
                "offsetInEndSection": 2124, 
                "text": "Of the oral agents approved for treating PAH at the time of this study, sildenafil was most commonly prescribed as index therapy and was also associated with the lowest costs, largely due to significantly lower pharmacy costs. This study is characterized by limitations inherent to claims database analyses, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16194131", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 332, 
                "text": "Erectile dysfunction (ED) affects approximately 30 million men in the United States. The objectives of this study were to (1) assess the cost and utilization of sildenafil citrate (Viagra), an oral therapeutic agent for ED, in a large managed care organization (MCO) with a quantity limit of 6 units per 30-day supply and"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16194131", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1480, 
                "offsetInEndSection": 2004, 
                "text": "The total allowed charges for sildenafil pharmacy claims in 2001 were 3.56 million US dollars, of which patients paid 26.6% in average cost-share, and the net MCO cost per member per month (PMPM) was 0.18 US dollars. A total of 1,681 patients (8.3%) exceeded their quantity restrictions for sildenafil tablets in 2001, of which 1,362 (81.0%) paid cash and 319 (19.0%, or 1.6% of all sildenafil users) appealed and received approval from the MCO for additional sildenafil tablets beyond the restriction of 6 tablets per month"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16194131", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2211, 
                "offsetInEndSection": 2469, 
                "text": "A quantity limit of 6 tablets of sildenafil per 30-day period was associated with a drug cost to users and the MCO of 0.25 US dollars PMPM. Sildenafil users paid an average cost-share of 26.6%, resulting in a net drug cost of 0.18 US dollars PMPM to the MCO."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10345973", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 827, 
                "offsetInEndSection": 1008, 
                "text": "Managed care companies are expected to counter runaway pharmacy costs for sildenafil by excluding it from coverage, imposing significant limitations, or requiring higher copayments."
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "Does HER2 under-expression lead to favorable response to trastuzumab?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020869", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786", 
            "http://www.biosemantics.org/jochem#4002084", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018734", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005176", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0038128", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010467", 
            "http://www.disease-ontology.org/api/metadata/DOID:0060079", 
            "http://www.disease-ontology.org/api/metadata/DOID:0060080"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23082154", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22711713", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22658319", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22580986", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21709140", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20392785", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19920112", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19624808", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19606230", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19435924", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18534031", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12503030", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11148461"
        ], 
        "exact_answer": "No", 
        "id": "51542eacd24251bc05000084", 
        "ideal_answer": "No, trastuzumab is effective only in cancers where Her2 is over-expessed.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23082154", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 961, 
                "offsetInEndSection": 1117, 
                "text": "trastuzumab (Herceptin\u00ae) an antibody-based therapy exists which is successfully used clinically for targeting HER2 in metastatic HER2-positive breast cancer"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 211, 
                "offsetInEndSection": 331, 
                "text": "over-expression of HER2 is reported in approximately 20% of gastric tumours, challenging the use of targeted therapies. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 526, 
                "offsetInEndSection": 802, 
                "text": "In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. Addition of trastuzumab to chemotherapy did not increase the incidence of adverse events."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658319", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 348, 
                "offsetInEndSection": 408, 
                "text": "treatment of HER2-overexpressing breast cancer: trastuzumab,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580986", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 173, 
                "offsetInEndSection": 354, 
                "text": "Trastuzumab has demonstrated clinical activity in several types of HER2-overexpressing epithelial tumors, such as breast and metastatic gastric or gastroesophageal junction cancer. "
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21709140", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 7981, 
                "offsetInEndSection": 8131, 
                "text": "trastuzumabThe Panel unanimously supported the use of 1 year of trastuzumab as standard adjuvant treatment for patients with \u2018HER2 positive\u2019 disease, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392785", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1621, 
                "offsetInEndSection": 1817, 
                "text": "An example is the established benefit of trastuzumab as adjuvant therapy for breast cancer; a clear definition of HER2-positivity and the assay reproducibility have, however, remained unanswered. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920112", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 136, 
                "text": "Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624808", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 400, 
                "offsetInEndSection": 587, 
                "text": "Without contraindication HER2 protein overexpression (or HER2 gene amplification) represents the worldwide accepted rationale for antibody-targeted therapy using trastuzumab (Herceptin\u2122)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606230", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 153, 
                "offsetInEndSection": 341, 
                "text": " anti-HER2 monoclonal antibody trastuzumab (Tzb; Herceptin\u00ae), the first immunotherapeutic drug for the successful treatment of breast carcinomas overexpressing the HER2 (erbB-2) oncogene ["
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435924", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 350, 
                "text": "Human epidermal growth factor receptor 2 (HER2/neu) is an important target for the treatment of the breast cancers in which it is overexpressed. However, no approved anti-HER2/neu therapy is available for the majority of breast cancer patients, who express HER2/neu at low levels (with scores of 1+ or 2+/fluorescence in situ hybridization-negative)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18534031", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 570, 
                "offsetInEndSection": 724, 
                "text": "effective targeted therapies such as Trastuzumab (Herceptin), a monoclonal antibody to HER2, which are effective only in tumors with HER2 overexpression, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503030", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 146, 
                "text": "The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) is useful in the treatment of ErbB2-overexpressing breast cancers,"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148461", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 280, 
                "text": "HercepTestTM (DAKO A/S, Glostrup, Denmark) is an immunohistochemical assay that detects HER2/neu gene products, and evaluates the overexpression status of the HER2/neu protein in determining eligibility for the Trastuzumab (HerceptinR, Genentech, San Francisco, CA, USA) therapy. "
            }
        ], 
        "triples": [
            {
                "o": "Trastuzumab", 
                "p": "http://www.w3.org/2000/01/rdf-schema#label", 
                "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00072"
            }, 
            {
                "o": "http://linkedlifedata.com/resource/umls/label/A10771788", 
                "p": "http://linkedlifedata.com/resource/umls/altMetaMap", 
                "s": "http://linkedlifedata.com/resource/umls/id/C0728747"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A10771788"
            }, 
            {
                "o": "trastuzumab", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A1545807"
            }, 
            {
                "o": "TRASTUZUMAB", 
                "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
                "s": "http://linkedlifedata.com/resource/umls/label/A8438296"
            }, 
            {
                "o": "http://www.w3.org/2008/05/skos-xl#Label", 
                "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
                "s": "http://linkedlifedata.com/resource/umls/label/A1545806"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001798", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016229", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023582", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001773", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23054683", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23030236", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22155483", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21709374", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21548758", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23528227"
        ], 
        "exact_answer": "Yes", 
        "id": "5156beb4d24251bc05000089", 
        "ideal_answer": "Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23054683", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 469, 
                "offsetInEndSection": 783, 
                "text": "miRNAs are aberrantly expressed in AD, and these have been implicated in the regulation of amyloid-\u03b2 (A\u03b2) peptide, tau, inflammation, cell death, and other aspects which are the main pathomechanisms of AD. In addition, regulation of miRNAs varies in blood, and cerebral spinal fluid may indicate alterations in AD."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030236", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 251, 
                "offsetInEndSection": 407, 
                "text": "miRNA microarray analysis was carried out on blood of rats at 1 week and 2 months after injection. RESULTS: Many up- and downregulated miRNAs were detected."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030236", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 536, 
                "offsetInEndSection": 712, 
                "text": "Blood miRNAs could be useful as biomarkers for exposure to nanoparticles. miR-298 regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1) in Alzheimer's disease."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155483", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 115, 
                "offsetInEndSection": 484, 
                "text": " We previously studied microRNAs (miRNAs) in AD autopsy brain samples and reported a connection between miR-137, -181c, -9, -29a/b and AD, through the regulation of ceramides. In this study, the potential role of these miRNAs as diagnostic markers for AD was investigated. We identified that these miRNAs were down-regulated in the blood serum of probable AD patients. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548758", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 173, 
                "offsetInEndSection": 399, 
                "text": "287 with Alzheimer disease (AD) as compared with 344 age- and gender-matched controls. In addition, we evaluated expression levels of hnRNP-A1 and its regulatory microRNA (miR)-590-3p in blood cells from patients and controls."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548758", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1240, 
                "offsetInEndSection": 1470, 
                "text": "Decreased relative expression levels of hsa-miR-590-3p was observed in patients with AD versus controls (0.685\u2009\u00b1\u20090.080 versus 0.931\u2009\u00b1\u20090.111, p\u2009=\u20090.079), and correlated negatively with hnRNP-A1 mRNA levels (r\u2009=\u2009-0.615, p\u2009=\u20090.0237)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1630, 
                "offsetInEndSection": 1891, 
                "text": ".Gene expression studies in AD have shown substantial downregulation of various mRNA species in brain (Pasinetti, 2001), peripheral blood mononuclear cells (BMC) (Maes et al. 2006) and lymphocytes (Scherzer et al. 2004) relative to non-demented control values. "
            }, 
            {
                "beginSection": "sections.3", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.3", 
                "offsetInBeginSection": 457, 
                "offsetInEndSection": 629, 
                "text": "We found that human BMC expressed a broad range of miRNAs, representing 20% of the 462 miRNA spotted on nitrocellulose membranes in the array format (Supplemental Table 2)."
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 1266, 
                "offsetInEndSection": 1402, 
                "text": ".We observed slightly different levels of miRNA expression between male and female BMC as illustrated by the heat map generated by GSEA "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19936094", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2509, 
                "offsetInEndSection": 2886, 
                "text": "we screened 462 human miRNA (from let-7 family to miR-663) in BMC derived from well-characterized cases of mild sporadic AD and age-matched normal elderly control subjects and, based on predicted miRNA targets, ascertained whether the accruing data may account for the patterns of mRNA downregulation in Alzheimer BMC previously reported by our laboratories (Maes et al. 2006)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 622, 
                "offsetInEndSection": 809, 
                "text": "expression analysis of Sp1 and its regulatory microRNAs (hsa-miR-29b and hsa-miR-375) has been performed in peripheral blood mononuclear cells (PBMCs), together with Sp1 protein analysis."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1308, 
                "offsetInEndSection": 1427, 
                "text": "Significantly decreased relative expression levels of hsa-miR-29b, but not of hsa-miR-375, were observed in AD patients"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23435408", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1520, 
                "offsetInEndSection": 1684, 
                "text": "Sp1 and its regulatory hsa-miR-29b are deregulated in AD patients, possibly leading to aberrant production of downstream target genes involved in the pathogenesis. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528227", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 863, 
                "offsetInEndSection": 1282, 
                "text": "We previously observed that miR-137, -181c, -9, and 29a/b post-transcriptionally regulate SPT levels, and the corresponding miRNA levels in the blood sera are potential diagnostic biomarkers for AD. Here, we observe a negative correlation between cortical A\u03b242 and sera A\u03b242, and a positive correlation between cortical miRNA levels and sera miRNA levels suggesting their potential as noninvasive diagnostic biomarkers."
            }
        ], 
        "triples": [
            {
                "o": "Blood", 
                "p": "http://purl.uniprot.org/core/name", 
                "s": "http://purl.uniprot.org/pubmed/10477709"
            }, 
            {
                "o": "http://purl.uniprot.org/pubmed/10339464", 
                "p": "http://www.w3.org/2004/02/skos/core#exactMatch", 
                "s": "http://purl.uniprot.org/pubmed/10339464"
            }, 
            {
                "o": "Blood", 
                "p": "http://purl.uniprot.org/core/name", 
                "s": "http://purl.uniprot.org/pubmed/10572112"
            }, 
            {
                "o": "Blood", 
                "p": "http://purl.uniprot.org/core/name", 
                "s": "http://purl.uniprot.org/pubmed/11110714"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Which antiepileptic drug is most strongly associated with spina bifida? ", 
        "concepts": [
            "http://www.disease-ontology.org/api/metadata/DOID:0080016", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000927"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23082254", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22051200", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21766433", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19490036", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17075842", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11077457", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10339792", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8075508", 
            "http://www.ncbi.nlm.nih.gov/pubmed/2707392", 
            "http://www.ncbi.nlm.nih.gov/pubmed/3939491"
        ], 
        "exact_answer": [
            "Valproate"
        ], 
        "id": "51588bb2d24251bc05000091", 
        "ideal_answer": "Phenytoin is not used in pregnancy as it is associated with a severe fetal deformation. From the other anticonvulsants most studies report the higher association between use during pregnancy and spin bifida to occur with Valproate.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23082254", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 324, 
                "offsetInEndSection": 685, 
                "text": "The association among maternal epilepsy, anticonvulsant drugs, and an increased incidence of congenital abnormalities has been suspected for at least 25 years. Although, most anticonvulsant medications have been implicated as potential teratogens, phenytoin, valproic acid, carbamazepine, or a combination therapy with these compounds is involved most commonly "
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23082254", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 3, 
                "offsetInEndSection": 715, 
                "text": "DiscussionFetal hydantoin syndrome is a fetopathy likely to occur when a pregnant patient takes phenytoin for epileptic seizures. Phenytoin is a known teratogen and the FDA has labeled phenytoin as a category D medication because of its potential to cause significant, unreasonable harm to a fetus. Approximately, 2% of women giving birth are epileptic and phenytoin is prescribed in 5%\u221220% of patients. The risk that an infant exposed to hydantoin in utero will have the clinical phenotype of the full-blown fetal hydantoin syndrome is approximately 5%\u201310%, whereas the risk of an infant's expressing some effects of the syndrome is 33% [3, 4]. Phenytoin interferes with the body's ability to absorb folic acid."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22051200", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 258, 
                "text": "The teratogenicity of antiepilepsy drug valproic acid (VPA) mostly is found in genetic and somatic levels, causing teratogenesis involving neurotubular defects (NTDs), anencephaly, lumbosacral meningomyelocele, and leg dysfunction due to spina bifida aperta."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21766433", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 721, 
                "offsetInEndSection": 1062, 
                "text": "The summary odds ratio estimate for the association between valproic acid and spina bifida was 11.9 (95% uncertainty interval (UI): 4.0-21.2); for valproic acid and cleft palate 5.8 (95% UI: 3.3-9.5); for carbamazepine and spina bifida 3.6 (95% UI: 1.3-7.8); and for carbamazepine and cleft palate 2.4 (95% UI: 1.1-4.5) in the United States."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19490036", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1030, 
                "offsetInEndSection": 1307, 
                "text": "Increased risk for MCMs could be demonstrated only for exposure to valproate (5.6%, p = 0.005) and AED polytherapy (6.1%, p = 0.02). Neonatal spina bifida was not significantly increased, but was a major indication for elective pregnancy termination among women with epilepsy. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17075842", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 316, 
                "text": "Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population. Failure of the neural tube to close during development results in exencephaly or anencephaly, as well as spina bifida."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11077457", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1034, 
                "offsetInEndSection": 1095, 
                "text": "Associations were found for spina bifida with valproic acid. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10339792", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 95, 
                "text": "Fetal exposure to valproic acid or carbamazepine increases the risk of neural tube defect (NTD)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8075508", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 684, 
                "text": "Women with epilepsy giving birth during 1973 to 1991 were identified by record linkage of Swedish health registries. Among 3,625 identified infants, 9 had spina bifida. A nested case-control study was performed, comparing drugs used in early pregnancy in the 9 cases and in 18 controls, matched for year of delivery, maternal age, and parity. Six of the spina bifida mothers had used carbamazepine and two had used valproic acid. Among the controls, 5 women used carbamazepine and one valproic acid. There is an apparent excess risk for spina bifida after use of either of these two drugs, but it is not statistically significant when the analysis is restricted to drug-using women. T"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2707392", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 459, 
                "offsetInEndSection": 623, 
                "text": "A significant association was seen between maternal use of valproic acid and spina bifida, and a weaker, non-significant one between carbamazepine and spina bifida."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/3939491", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 988, 
                "text": "A statistically significant association between Spina Bifida and Valproic Acid (odds ratio 22.7; Fisher p value = 0.0364) was observed: no other anticonvulsant tested showed any association with any type of malformation."
            }
        ], 
        "type": "factoid"
    }, 
    {
        "body": "Where in the cell do we find the protein Cep135?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/CP135_HUMAN"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23456457", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23213374", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23115304", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22976301", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22898782", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22521416", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22261722", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21766470", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20392737", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19454482", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19321663", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19293139", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18851962", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17681131", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16240430", 
            "http://www.ncbi.nlm.nih.gov/pubmed/14983524", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11781336", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10842375"
        ], 
        "exact_answer": [
            "centrosome"
        ], 
        "id": "51596a8ad24251bc0500009e", 
        "ideal_answer": "Cep135 is the active component of the centrosome.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23456457", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 163, 
                "offsetInEndSection": 220, 
                "text": "CEP family protein is the active component of centrosome "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23213374", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1179, 
                "offsetInEndSection": 1231, 
                "text": " Cep135 was associated mostly with mother centrioles"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976301", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 144, 
                "text": "Cep135/Bld10 is a conserved centriolar protein required for the formation of the central cartwheel, an early intermediate in centriole assembly."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22976301", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 939, 
                "offsetInEndSection": 1157, 
                "text": "Thus, in flies, Cep135/Bld10 is not essential for cartwheel assembly or for establishing the ninefold symmetry of centrioles; rather, it appears to stabilize the connection between inner and outer centriole components."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14983524", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 110, 
                "text": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521416", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 634, 
                "offsetInEndSection": 675, 
                "text": "135&nbsp;kDa centrosomal protein (CEP135)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18851962", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 301, 
                "offsetInEndSection": 415, 
                "text": "In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321663", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 349, 
                "offsetInEndSection": 520, 
                "text": " Drosophila Bld10, the ortholog of Chlamydomonas reinhardtii Bld10p and human Cep135, is a ubiquitous centriolar protein that also localizes to the spermatid basal body. M"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898782", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 119, 
                "text": "BLD10/CEP135 is a microtubule-associated protein that controls the formation of the flagellum central microtubule pair."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392737", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 683, 
                "offsetInEndSection": 877, 
                "text": "We found an evolutionarily cohesive and ancestral module, which we term UNIMOD and is defined by three components (SAS6, SAS4/CPAP and BLD10/CEP135), that correlates with the occurrence of CBBs."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22261722", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 717, 
                "offsetInEndSection": 783, 
                "text": "pericentriolar material proteins including pericentrin and CEP135."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17681131", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 690, 
                "offsetInEndSection": 802, 
                "text": "hereas Cep135 and CPAP formed a core structure within the proximal lumen of both parental and nascent centrioles"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21766470", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 960, 
                "offsetInEndSection": 1017, 
                "text": ". Centrosome components, including \u03b3-tubulin and Cep135, "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10842375", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 257, 
                "offsetInEndSection": 324, 
                "text": "suggesting that Cep135 is a structural component of the centrosome."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11781336", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 4120, 
                "offsetInEndSection": 4220, 
                "text": "It is thus suggested that Cep135 may play an important role in organizing the functional centrosome."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11781336", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3597, 
                "offsetInEndSection": 3708, 
                "text": " Cep135 is present in a wide range of organisms, indicating that it is a universal component of the centrosome."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11781336", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 124, 
                "text": "Characterization of Cep135, a novel coiled-coil centrosomal protein involved in microtubule organization in mammalian cells."
            }
        ], 
        "type": "factoid"
    }, 
    {
        "body": "In which isochores are Alu elements enriched?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D032085", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020087"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/22057813", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19543403", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15871047", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11591470", 
            "http://www.ncbi.nlm.nih.gov/pubmed/9931467", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8828040", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7723057", 
            "http://www.ncbi.nlm.nih.gov/pubmed/6572942"
        ], 
        "exact_answer": [
            [
                "H2"
            ], 
            [
                "H3"
            ]
        ], 
        "id": "515bd543298dcd4e51000001", 
        "ideal_answer": "Alu elements are enriched in high GC% isochores due to reduced Alu loss by recombination in these regions. The frequency of Alu sequences increases with increasing GC, but attains a maximum in H2 isochores.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057813", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 146, 
                "offsetInEndSection": 241, 
                "text": " the vast majority of Alu sequences were shown to have the highest density in GC-rich isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057813", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 988, 
                "offsetInEndSection": 1103, 
                "text": "Alu sequences being unstable in the GC-poor isochores but stable in the compositionally matching GC-rich isochores,"
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543403", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 257, 
                "offsetInEndSection": 406, 
                "text": "he increase in insertions and deletions in the H1-H3 isochore families, parallels the increase in the concentration of both Alu sequences and genes ("
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543403", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 3306, 
                "offsetInEndSection": 3561, 
                "text": "The density of insertions/deletions increased with increasing GC of isochore families, essentially paralleling the densities of genes and Alu sequences, except for the lower values of the longest (>1000 bp, base pairs) insertions/deletions in H3 isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871047", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 152, 
                "text": "Alu retrotransposons do not show a homogeneous distribution over the human genome but have a higher density in GC-rich (H) than in AT-rich (L) isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15871047", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1230, 
                "offsetInEndSection": 1463, 
                "text": "This result, together with the known higher selective disadvantage of recombination products in H isochores, points to Alu-Alu recombination as the main agent provoking the density shift of Alus toward the GC-rich parts of the genome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11591470", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 175, 
                "offsetInEndSection": 235, 
                "text": "whereas GC-rich Alus are mostly present in GC-rich isochores"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11591470", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1221, 
                "offsetInEndSection": 1469, 
                "text": "the present results on Alu and LINE stability/exclusion predict significant losses of Alu DNA from the GC-poor isochores during evolution, a phenomenon apparently due to negative selection against sequences that differ from the isochore composition"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931467", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 780, 
                "offsetInEndSection": 929, 
                "text": "The frequency of Alu sequences also increases with increasing GC, but attains a maximum in H2 isochores, in agreement with previous experimental data"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/9931467", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1570, 
                "offsetInEndSection": 1643, 
                "text": "The CpG levels of both Alus and CpG islands increase with their GC levels"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8828040", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 327, 
                "offsetInEndSection": 416, 
                "text": "characterized as a GC-rich isochore enriched for CpG islands, genes, and Alu-like repeats"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7723057", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1299, 
                "offsetInEndSection": 1414, 
                "text": "Microsatellites and SINES (Alu, B1, B2) are found at roughly equal frequencies in introns from all isochore classes"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/6572942", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 500, 
                "offsetInEndSection": 776, 
                "text": "The results indicate that the short repeats of the B1 family of mouse and of the Alu I family of man are most frequent in the heavy components, whereas the long repeats of the BamHI family of mouse and of the Kpn I family of man are mainly present in the two light components."
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "Which forms of cancer is the Tpl2 gene associated with?", 
        "concepts": [
            "http://www.disease-ontology.org/api/metadata/DOID:162", 
            "http://www.uniprot.org/uniprot/M3K8_RAT"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23457529", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23064365", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22451924", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15575964"
        ], 
        "exact_answer": [
            [
                "Skin cancer"
            ], 
            [
                "ADI prostate cancer"
            ], 
            [
                "gastric adenocarcinoma"
            ], 
            [
                "colon adenocarcinoma"
            ], 
            [
                "colitis-associated cancer (CAC)"
            ], 
            [
                "breast cancer"
            ], 
            [
                "Hodgkin lymphoma"
            ], 
            [
                "nasopharyngeal carcinoma"
            ], 
            [
                "T-cell neoplasia"
            ]
        ], 
        "id": "515bf6d6298dcd4e51000004", 
        "ideal_answer": "Tpl2/Map3K8, also known as tumor progression locus 2 has been identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers. Types of cancer associated with Tpl2 include skin and epithelial cancers, ADI prostate cancer, gastric and colon adenocarcinomas, colitis-associated cancer (CAC), breast cancer, Hodgkin lymphomas, nasopharyngeal carcinomas and several types of T-cell neoplasias.", 
        "snippets": [
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23457529", 
                "endSection": "title", 
                "offsetInBeginSection": 44, 
                "offsetInEndSection": 94, 
                "text": "increased skin tumorigenesis in tpl2 knockout mice"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23457529", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1464, 
                "offsetInEndSection": 1596, 
                "text": "These experiments illustrate COX-2 induction in the absence of Tpl2 may be responsible for the increased tumorigenesis found in mice"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064365", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1344, 
                "offsetInEndSection": 1485, 
                "text": "These findings establish a mesenchyme-specific role for Tpl2 in the regulation of HGF production and suppression of epithelial tumorigenesis."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064365", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 96, 
                "text": "Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22451924", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 64, 
                "text": "Tpl2 ablation promotes intestinal inflammation and tumorigenesis"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 102, 
                "text": "TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3926, 
                "offsetInEndSection": 4136, 
                "text": "the suppression of TPL2 diminishes ADI prostate cancer growth and a high frequency of TPL2 overexpression in human ADI prostate cancer samples validates TPL2 as a target for the treatment of this deadly disease"
            }, 
            {
                "beginSection": "sections.4", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21267413", 
                "endSection": "sections.4", 
                "offsetInBeginSection": 6982, 
                "offsetInEndSection": 7091, 
                "text": "Alternative activation of the MEK/ERK pathway and NF-\u03baB by TPL2 contribute to ADI prostate cancer cell growth"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 113, 
                "text": "Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 170, 
                "offsetInEndSection": 281, 
                "text": " Previously identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935675", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1189, 
                "offsetInEndSection": 1390, 
                "text": "These studies indicate that Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis, with its absence contributing to both tumorigenesis and inflammation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1073, 
                "offsetInEndSection": 1176, 
                "text": "Studies in human tumor specimens have shown that Tpl2/Cot is overexpressed in early stage breast cancer"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1182, 
                "offsetInEndSection": 1303, 
                "text": "in EBV-related Hodgkin lymphomas and nasopharyngeal carcinomas [10] and occasionally in gastric and colon adenocarcinomas"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 62, 
                "text": "Expression of the Tpl2/Cot oncogene in human T-cell neoplasias"
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15575964", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 3190, 
                "offsetInEndSection": 3467, 
                "text": "ll the Tpl2/Cot overexpressing patients had LGL-PD, three with the phenotype of CD3+ T-LGL leukemia and one with the CD3- pattern of chronic NK-lymphocytosis. Three of these patients displayed neutropenia not attributable to BM infiltration, one in association with sarcoidosis"
            }
        ], 
        "triples": [
            {
                "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/TPL2", 
                "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene", 
                "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/3003"
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "What is the INSURE procedure in premature babies.", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007234", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D047928"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23336160", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22430447", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22266202", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21506654", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20642659", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20616570", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20545934", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20180736", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19679893", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18841536", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17476269", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17069738", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10218338", 
            "http://www.ncbi.nlm.nih.gov/pubmed/557175", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23359581", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23320153"
        ], 
        "id": "515db54c298dcd4e51000016", 
        "ideal_answer": "InSurE stands for Intubation-surfactant-extubation and is a method in the treatment of neonatal respiratory distress syndrome (NRDS)", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23336160", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 63, 
                "offsetInEndSection": 178, 
                "text": " intubation-surfactant-extubation (INSURE) method in the treatment of neonatal respiratory distress syndrome (NRDS)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23336160", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1563, 
                "offsetInEndSection": 1721, 
                "text": "INSURE method can improve the oxygenation function of the lung, decrease the incidence of VAP and shorten the duration of oxygen therapy in neonates with NRDS"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430447", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 66, 
                "offsetInEndSection": 113, 
                "text": "intubation, surfactant, and extubation (InSurE)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22430447", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 311, 
                "text": "Nasal continuous positive airway pressure (NCPAP) plus intubation, surfactant, and extubation (InSurE) with the option of back-up ventilation for those infants for whom noninvasive ventilatory support failed resulted in a significant increase in survival in extremely low birth weight (ELBW) infants."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266202", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 280, 
                "text": "The INSURE method, which consists of an intubation-surfactant-extubation sequence, is effective in reducing the need for mechanical ventilation (MV), the duration of respiratory support, and the need for surfactant replacement in preterm infants with respiratory distress syndrome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21506654", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 63, 
                "offsetInEndSection": 115, 
                "text": "intubation-surfactant-extubation (INSURE) procedures"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20642659", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 301, 
                "offsetInEndSection": 374, 
                "text": " INSURE (Intubation SURfactant Extubation) procedure in preterm neonates."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616570", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 994, 
                "offsetInEndSection": 1045, 
                "text": "INtubation-SURfactant-Extubation (INSURE) treatment"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545934", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 11, 
                "offsetInEndSection": 242, 
                "text": "Surfactant given during brief intubation followed by immediate extubation on nasal continuous positive airway pressure [Intubation-Surfactant-Extubation (InSurE) approach] is used to treat respiratory distress syndrome in newborns."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20180736", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 120, 
                "offsetInEndSection": 168, 
                "text": "INSURE (intubatio-surfactant-extubation) method "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19679893", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 12, 
                "offsetInEndSection": 209, 
                "text": "In preterm infants with respiratory distress syndrome (RDS) nasal continuous positive airway pressure (nCPAP) with the \"InSurE\" procedure (intubation, surfactant, extubation) is increasingly used. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18841536", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 92, 
                "offsetInEndSection": 247, 
                "text": "INSURE method ( INtubation- SURfactant- Extubation) during nasal continuous positive airway pressure for preterm infants with respiratory distress syndrome"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17476269", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 48, 
                "offsetInEndSection": 287, 
                "text": "a method for surfactant administration by transient intubation, INSURE (i.e. INtubation SURfactant Extubation) during nasal continuous positive airway pressure (nCPAP) for moderately preterm infants with respiratory distress syndrome (RDS)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17069738", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 271, 
                "offsetInEndSection": 392, 
                "text": "(INSURE method: INtubation-SURfactant-Extubation) during treatment with nasal Continuous Positive Airway Pressure (CPAP)."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10218338", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 380, 
                "offsetInEndSection": 573, 
                "text": "INSURE (Intubation-SURfactant-Extubation) approach--i.e., surfactant therapy during brief intubation, immediately followed by extubation and continuous positive airway pressure (CPAP) treatment"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359581", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 251, 
                "offsetInEndSection": 301, 
                "text": "InSurE (Intubate, Surfactant, Extubate) procedure."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23320153", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 456, 
                "offsetInEndSection": 498, 
                "text": " Intubation-SURfactant-Extubation (INSURE)"
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "Which species may be used for the biotechnological production of itaconic acid?", 
        "concepts": [
            "http://www.biosemantics.org/jochem#4276340", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005656", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001426", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0047370", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0047613"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23420787", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23397482", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23298766", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22956279", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22752264", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
            "http://www.ncbi.nlm.nih.gov/pubmed/21324422", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20461508", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17697977", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17451943", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12146646", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1366363"
        ], 
        "exact_answer": [
            [
                "Aspergillus terreus"
            ], 
            [
                "Aspergillus niger"
            ], 
            [
                "Ustilago maydis"
            ]
        ], 
        "id": "515ffc2b298dcd4e51000035", 
        "ideal_answer": "In 1955, the production of itaconic acid was firstly described for Ustilago maydis.  Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media. Itaconic acid is mainly supplied by biotechnological processes with the fungus Aspergillus terreus. Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different host organism.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1366363", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 4, 
                "offsetInEndSection": 77, 
                "text": "continuous itaconic acid production from sucrose with Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12146646", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 104, 
                "text": "A potent itaconic acid producing strain, Aspergillus terreus SKR10, was isolated from horticulture waste"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12146646", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 526, 
                "offsetInEndSection": 614, 
                "text": "Two high itaconic acid yielding mutants, N45 and UNCS1 were obtained by gradient plating"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17451943", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 87, 
                "text": "Itaconic acid production using sago starch hydrolysate by Aspergillus terreus TN484-M1."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697977", 
                "endSection": "title", 
                "offsetInBeginSection": 34, 
                "offsetInEndSection": 110, 
                "text": "production of itaconic acid and lovastatin by Aspergillus terreus ATCC 20542"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697977", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 201, 
                "text": "Fermentation products of Aspergillus terreus ATCC 20542 (a parent strain for lovastatin production) were collected, and the coexistence of itaconic acid (IA) with lovastatin was confirmed in this study"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20461508", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 57, 
                "text": "Enhancing itaconic acid production by Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20461508", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 83, 
                "text": "Aspergillus terreus is successfully used for industrial production of itaconic acid"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21324422", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 250, 
                "offsetInEndSection": 444, 
                "text": "From a number of different Aspergillus terreus controlled batch fermentations, those cultures with the largest difference in itaconic acid titer and productivity were selected for mRNA isolation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 942, 
                "offsetInEndSection": 1040, 
                "text": "itaconic acid is mainly supplied by biotechnological processes with the fungus Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2024, 
                "offsetInEndSection": 2100, 
                "text": "In 1955, the production of itaconic acid was firstly described for U. maydis"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22752264", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 236, 
                "offsetInEndSection": 335, 
                "text": " a systematic process optimization was performed with an own isolated strain of Aspergillus terreus"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 54, 
                "text": "Enhanced itaconic acid production in Aspergillus niger"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 301, 
                "offsetInEndSection": 373, 
                "text": "Currently, itaconic acid is produced commercially by Aspergillus terreus"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 696, 
                "offsetInEndSection": 888, 
                "text": "Based on its high citric acid producing capability and broad applicability in industry, Aspergillus niger (A. niger) was selected as a novel itaconic acid production host strain in recent work"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22925689", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1978, 
                "offsetInEndSection": 2111, 
                "text": "Therefore, over-expression of gpdA in A. niger CAD strains might increase itaconic acid producing level via enhanced glycolytic flux."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956279", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 151, 
                "text": "Cells of Aspergillus terreus, free and immobilized in polyurethane foam, were employed in itaconic acid fermentation processes on glycerol-based media."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298766", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 206, 
                "offsetInEndSection": 306, 
                "text": "current biotechnological production processes with the fungus Aspergillus terreus has to be improved"
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23397482", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 115, 
                "text": "Reduced by-product formation and modified oxygen availability improve itaconic acid production in Aspergillus niger"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23397482", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 140, 
                "offsetInEndSection": 304, 
                "text": " Previously, it was shown that expression of the cis-aconitate decarboxylase gene (cadA) from Aspergillus terreus converted A. niger into an itaconic acid producer "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420787", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 768, 
                "offsetInEndSection": 926, 
                "text": "Cloning of the cadA gene into the citric acid producing fungus A. niger showed that it is possible to produce itaconic acid also in a different host organism."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22480369", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1590, 
                "offsetInEndSection": 1705, 
                "text": "In this current study, itaconic acid fermentation was carried out with the mould fungus Ustilago maydis (U. maydis)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420787", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 247, 
                "offsetInEndSection": 416, 
                "text": "Some Aspergillus species, like A. itaconicus and A. terreus, show the ability to synthesize this organic acid and A. terreus can secrete significant amounts to the media"
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "What is the role of TRH in hypertension?", 
        "concepts": [
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001794", 
            "http://www.disease-ontology.org/api/metadata/DOID:10763", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008217", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062186", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007022", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006973", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001795", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018025", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013973", 
            "http://www.biosemantics.org/jochem#4254151", 
            "http://www.uniprot.org/uniprot/TRFR_BOVIN", 
            "http://www.uniprot.org/uniprot/TRFR_SHEEP", 
            "http://www.uniprot.org/uniprot/TRFR_MOUSE", 
            "http://www.uniprot.org/uniprot/TRFR_CHICK"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/17227965", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17137217", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11882596", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11566956", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11230301", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7498977", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7554113", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8039276", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1595355", 
            "http://www.ncbi.nlm.nih.gov/pubmed/2854272", 
            "http://www.ncbi.nlm.nih.gov/pubmed/3035513"
        ], 
        "id": "51602609298dcd4e5100003a", 
        "ideal_answer": "TRH gene overexpression induces hypertension in normal rats and spontaneously hypertensive rats have central TRH hyperactivity with increased TRH synthesis and release and an elevated TRH receptor number. TRH antisense treatment reduces hypertension.\ncentral TRH participates in the hypertension induced by body weight gain probably through its well-known action on sympathetic activity.\nthe pressor effect of intravenous TRH is mediated primarily by a stimulation of alpha-adrenergic receptors.  Activation of cardiac beta-adrenoceptors seems to contribute to the blood pressure increasing effect of intravenous TRH. Ang II system is involved in the TRH cardiovascular effects. \nPolymorphisms in  TRH (thyrotropin-releasing hormone) are significantly associated with both blood pressure variation and hypertension.\nTRH may mediate the central leptin-induced hypertension effect\nA parallel increase in the density of brain TRH receptors with elevation of blood pressure has been shown and suggests that brain TRH receptors may play an important role in the pathophysiology of hypertension. TRH Receptor gene participates in the etiopathogenesis of essential hypertension.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17227965", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 94, 
                "text": "We recently showed that diencephalic TRH may mediate the central leptin-induced pressor effect"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17227965", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1026, 
                "offsetInEndSection": 1167, 
                "text": "that central TRH participates in the hypertension induced by body weight gain probably through its well-known action on sympathetic activity."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17137217", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1097, 
                "offsetInEndSection": 1360, 
                "text": "Five polymorphisms in five genes, CAST(calpastatin), LIPC (hepatic lipase), SLC4A1 (band 3 anion transporter), TRH (thyrotropin-releasing hormone), and VWF (von Willebrand factor), were significantly associated with both blood pressure variation and hypertension."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11882596", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 140, 
                "offsetInEndSection": 422, 
                "text": "We previously reported that thyrotropin-releasing hormone (TRH) precursor gene overexpression induces hypertension in the normal rat and that spontaneously hypertensive rats have central TRH hyperactivity with increased TRH synthesis and release and an elevated TRH receptor number."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11882596", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1545, 
                "offsetInEndSection": 1797, 
                "text": "We propose that because leptin produces central TRH synthesis and release, obesity may induce hypertension through TRH system activation and that the TRH-leptin interaction may thus contribute to the strong association between hypertension and obesity."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566956", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 242, 
                "offsetInEndSection": 369, 
                "text": "We have described that TRH overexpression induces hypertension in a normal rat, which was reversed by TRH antisense treatment. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566956", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 370, 
                "offsetInEndSection": 492, 
                "text": "his treatment also reduces the central TRH hyperactivity in spontaneously hypertensive rats and normalizes blood pressure."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11566956", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1643, 
                "offsetInEndSection": 1761, 
                "text": "Our findings support the hypothesis that the TRHR gene participates in the etiopathogenesis of essential hypertension."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11230301", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 98, 
                "offsetInEndSection": 399, 
                "text": "Recently, we described that the TRH precursor gene overexpression induces hypertension in the normal rat. In addition, we published that spontaneously hypertensive rats (SHR) have central extrahypothalamic TRH hyperactivity with increased TRH synthesis and release and an elevated TRH receptor number."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11230301", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1093, 
                "offsetInEndSection": 1540, 
                "text": "the encephalic renin-angiotensin system seems to be crucial in the development and/or maintenance of hypertension in SHR, we investigated the effect of antisense inhibition of TRH on that system and found that TRH antisense treatment significantly diminished the elevated diencephalic angiotensin II (Ang II) content in the SHR without any effect in control animals, suggesting that the Ang II system is involved in the TRH cardiovascular effects."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11230301", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1556, 
                "offsetInEndSection": 1678, 
                "text": "he central TRH system seems to be involved in the etiopathogenesis of hypertension in this model of essential hypertension"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7498977", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1314, 
                "offsetInEndSection": 1639, 
                "text": "ong-term treatment with enalapril (5 mg/kg twice daily), which was effective in inhibiting serum angiotensin-converting enzyme activity by more than 50%, decreased arterial blood pressure and preoptic area TRH content of SHR, whereas another vasodilator, diltiazem (10 mg/kg every 8 hours), failed to produce a similar change"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8039276", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1126, 
                "offsetInEndSection": 1469, 
                "text": "the pressor effect of intravenous TRH is mediated primarily by a stimulation of alpha-adrenergic receptors. Adrenal medullectomy appears to enhance the blood pressure response to intravenous TRH. Activation of cardiac beta-adrenoceptors seems to contribute to the blood pressure increasing effect of intravenous TRH in medullectomized animals."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1595355", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 98, 
                "text": "Centrally administered thyrotropin-releasing hormone exerts a well documented hypertensive effect."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1595355", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 884, 
                "offsetInEndSection": 1046, 
                "text": "These results provide evidence for a role of endogenous brain thyrotropin-releasing hormone in the maintenance of hypertension in spontaneously hypertensive rats."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2854272", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 57, 
                "offsetInEndSection": 209, 
                "text": "in spontaneously hypertensive (SHR) rats the development of hypertension paralleled increases in brain receptors for thyrotropin-releasing hormone (TRH)"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2854272", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1165, 
                "offsetInEndSection": 1355, 
                "text": "The results suggest that in addition to the brain, TRH receptors in the spinal cord of SHR rats are also up-regulated and may also play an important role in the regulation of blood pressure."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/3035513", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1532, 
                "offsetInEndSection": 1781, 
                "text": "The results provide, for the first time, evidence for a parallel increase in the density of brain TRH receptors with elevation of blood pressure, and suggest that brain TRH receptors may play an important role in the pathophysiology of hypertension."
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "Which histone marks are deposited by Set7?", 
        "concepts": [
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042393", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016571", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016570", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495", 
            "http://www.uniprot.org/uniprot/SETD7_HALRO"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/21963854", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15200950", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12208845", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12086618"
        ], 
        "exact_answer": [
            [
                "H4K20 monomethylation"
            ], 
            [
                "H3K4 monomethylation"
            ]
        ], 
        "id": "5160412d298dcd4e5100003c", 
        "ideal_answer": "Set7 is  H4K20 monomethyltransferase. Upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation. Set7 (or some variant) has also been reported to perform mono-methylation on lysine-4 of H3.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 190, 
                "offsetInEndSection": 226, 
                "text": "the loss of H4 lysine 20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 286, 
                "offsetInEndSection": 351, 
                "text": "Transcriptionally competent regions lack H4 lysine 20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12086618", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 17, 
                "offsetInEndSection": 102, 
                "text": "a human histone H4 lysine 20 methyltransferase and cloned the encoding gene, PR/SET07"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208845", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 338, 
                "offsetInEndSection": 433, 
                "text": "Localization of PR-Set7 to mitotic chromosomes and subsequent increase in H4 Lys 20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15200950", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 698, 
                "offsetInEndSection": 842, 
                "text": "the H4-K20 methyltransferase PR-Set7. Indeed, upregulation of PR-Set7 expression upon loss of HCF-1 leads to improper mitotic H4-K20 methylation"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963854", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3180, 
                "offsetInEndSection": 3263, 
                "text": "SET7 performs mono-methylation on lysine-4 of H3 to exert its coactivation function"
            }
        ], 
        "type": "list"
    }, 
    {
        "body": "Are there any desmins present in plants?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/DESM_CHICK", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045098"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/20171226", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19026658", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18033728", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12529857", 
            "http://www.ncbi.nlm.nih.gov/pubmed/10929203", 
            "http://www.ncbi.nlm.nih.gov/pubmed/8752741", 
            "http://www.ncbi.nlm.nih.gov/pubmed/1694790", 
            "http://www.ncbi.nlm.nih.gov/pubmed/2659540", 
            "http://www.ncbi.nlm.nih.gov/pubmed/7460905"
        ], 
        "exact_answer": "No.", 
        "id": "5162e011298dcd4e51000049", 
        "ideal_answer": "No. Desmins are type III intermediate filament (IF) proteins that have been identified to date only in metazoa (human, Danio rerio, bovine). Desmins are also associated with severe forms of skeletal, cardiac and myofibrillar myopathies.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20171226", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 155, 
                "text": "Inherited mutations in the gene coding for the intermediate filament protein desmin have been demonstrated to cause severe skeletal and cardiac myopathies."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026658", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 228, 
                "text": "Mutations in the intermediate filament (IF) protein desmin cause severe forms of myofibrillar myopathy characterized by partial aggregation of the extrasarcomeric desmin cytoskeleton and structural disorganization of myofibrils."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18033728", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 135, 
                "offsetInEndSection": 479, 
                "text": "The family of 70 intermediate filament genes (including those encoding keratins, desmins, and lamins) is now known to be associated with a wide range of diverse diseases, at least 72 distinct human pathologies, including skin blistering, muscular dystrophy, cardiomyopathy, premature aging syndromes, neurodegenerative disorders, and cataract. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529857", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 75, 
                "text": "Mutations in desmin have been associated with a subset of human myopathies."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10929203", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 99, 
                "text": "Characterization of a zebrafish (Danio rerio) desmin cDNA: an early molecular marker of myogenesis."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12529857", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 93, 
                "text": "Acute effects of desmin mutations on cytoskeletal and cellular integrity in cardiac myocytes."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/10929203", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 293, 
                "text": "Desmin is a muscle-specific protein and a constitutive subunit of the intermediate filaments (IF) in skeletal, cardiac and smooth muscles. It is an early marker of skeletal muscle myogenesis. We have characterized a clone of desmin cDNA from an embryonic zebrafish (Danio rerio) cDNA library. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/8752741", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1055, 
                "offsetInEndSection": 1246, 
                "text": "Immunohistochemical investigation showed a positive reaction for smooth muscle actin and desmins in the spindle cells proliferated in the lymph nodes; no cytokeratin positivity was detected. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/1694790", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 182, 
                "text": "We have raised monoclonal antibodies (Mab) to the Mr 55,000 desmin polypeptide, electrophoretically purified from cytoskeletal preparations of isolated bovine heart Purkinje fibers. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/2659540", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 237, 
                "offsetInEndSection": 409, 
                "text": "Mesothelial and ovarian carcinoma cells could not be distinguished by (intermediate) filament typing, using monoclonal antibodies (MAbs) to keratins, vimentins and desmins."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/7460905", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 201, 
                "text": "A fast and convenient procedure for the purification of polymerization-competent smooth-muscle desmin is described. Desmin from chicken gizzard and hog stomach were compared by fingerprint techniques. "
            }
        ], 
        "triples": [
            {
                "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0005882", 
                "p": "http://www.w3.org/2004/02/skos/core#broader", 
                "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0045098"
            }
        ], 
        "type": "yesno"
    }, 
    {
        "body": "Is it possible to detect survivin protein expression in normal human adult tissues?", 
        "concepts": [
            "http://www.uniprot.org/uniprot/BIRC5_HUMAN", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014024", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0009888", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0048729"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23132836", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17163847", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16619249", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15990723", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15195112", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15138808", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12671708", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22930255", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20514400", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18376799"
        ], 
        "id": "516425ff298dcd4e51000051", 
        "ideal_answer": "Most normal adult tissues do not express survivin, thymus and testis are the only exceptions.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17163847", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 156, 
                "offsetInEndSection": 455, 
                "text": "Application of this antibody to determine survivin expression in human normal adult tissues revealed that most adult tissues do not express survivin and, where it is present, survivin is largely restricted to a small subset of epithelial cells and cells with proliferative potential such as thymus. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17163847", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 601, 
                "offsetInEndSection": 722, 
                "text": "Testis is the only human adult tissue highly expressing survivin, with 60-70% positivity in the nuclei of spermatogonia. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16619249", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 165, 
                "text": "Survivin, a member of the inhibitor of apoptosis protein family, is expressed in most human cancers, but undetectable in normal differentiated adult tissue in vivo. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15990723", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 147, 
                "offsetInEndSection": 295, 
                "text": "Its expression is developmentally regulated: present during fetal development, it is undetectable in terminally differentiated normal adult tissue. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15195112", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 124, 
                "text": "Survivin is a novel inhibitor of apoptosis. It is detected in fetal and neoplastic adult tissue, but not in normal tissues. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18376799", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 94, 
                "offsetInEndSection": 261, 
                "text": "Survivin is expressed during embryonic and fetal development, selectively over-expressed in common human cancers and completely down-regulated in normal adult tissue. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514400", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 73, 
                "offsetInEndSection": 207, 
                "text": "Survivin, a member of the inhibitor of apoptosis proteins, is overexpressed in most cancers but is absent in most normal adult tissue."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514400", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 888, 
                "offsetInEndSection": 943, 
                "text": "However, survivin was not detected in non-tumor tissues"
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22930255", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 213, 
                "text": "Survivin and livin are two members of the inhibitor of apoptosis gene family, which have been found to be expressed in many human cancer tissues. But their expression could not be detected in normal adult tissue. "
            }, 
            {
                "beginSection": "sections.2", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12671708", 
                "endSection": "sections.2", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 165, 
                "text": "Survivin mRNA was found to be diffusely expressed during foetal development, but unusually, among the IAP family, it was generally not found in normal adult tissues."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15138808", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1273, 
                "offsetInEndSection": 1519, 
                "text": "n addition, the fact that survivin was only detected in urine samples of patients with bladder cancer, rather than in normal adult tissue (except thymus gland), suggests that survivin can be used as an ideal target in bladder carcinoma treatment."
            }
        ], 
        "type": "summary"
    }, 
    {
        "body": "How do histone methyltransferases cause histone modification?", 
        "concepts": [
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0016570", 
            "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008469", 
            "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011495"
        ], 
        "documents": [
            "http://www.ncbi.nlm.nih.gov/pubmed/23195220", 
            "http://www.ncbi.nlm.nih.gov/pubmed/23150054", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22483804", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22476432", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22393255", 
            "http://www.ncbi.nlm.nih.gov/pubmed/22357272", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20305384", 
            "http://www.ncbi.nlm.nih.gov/pubmed/20026581", 
            "http://www.ncbi.nlm.nih.gov/pubmed/19571682", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18846226", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18498648", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18231586", 
            "http://www.ncbi.nlm.nih.gov/pubmed/18058811", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17846168", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17584191", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17548343", 
            "http://www.ncbi.nlm.nih.gov/pubmed/17468742", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16581777", 
            "http://www.ncbi.nlm.nih.gov/pubmed/16409643", 
            "http://www.ncbi.nlm.nih.gov/pubmed/15775980", 
            "http://www.ncbi.nlm.nih.gov/pubmed/14690609", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12893173", 
            "http://www.ncbi.nlm.nih.gov/pubmed/12154089", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11850410", 
            "http://www.ncbi.nlm.nih.gov/pubmed/11316813"
        ], 
        "id": "51659356298dcd4e5100005a", 
        "ideal_answer": "Histone methyltransferases (HMTs) are responsible for the site-specific addition of covalent modifications on the histone tails, which serve as markers for the recruitment of chromatin organization complexes. There are two major types of HMTs: histone-lysine N-Methyltransferases and histone-arginine N-methyltransferases. The former methylate specific lysine (K) residues such as 4, 9, 27, 36, and 79 on histone H3 and residue 20 on histone H4. The latter methylate arginine (R) residues such as 2, 8, 17, and 26 on histone H3 and residue 3 on histone H4. Depending on what residue is modified and the degree of methylation (mono-, di- and tri-methylation), lysine methylation of histones is linked to either transcriptionally active or silent chromatin.", 
        "snippets": [
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23195220", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 306, 
                "text": "Lysine methylation of histones is associated with both transcriptionally active chromatin and with silent chromatin, depending on what residue is modified. Histone methyltransferases and demethylases ensure that histone methylations are dynamic and can vary depending on cell cycle- or developmental stage."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150054", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 512, 
                "offsetInEndSection": 706, 
                "text": "This approach identified Txr1p as a histone methyltransferase in Tetrahymena thermophila and characterized the relationships of the Txr1p and Ezl2p methyltransferases to histone H3 modification."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22483804", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 363, 
                "text": "Histone methyltransferases catalyze site-specific deposition of methyl groups, enabling recruitment of transcriptional regulators. In mammals, trimethylation of lysine 4 in histone H3, a modification localized at the transcription start sites of active genes, is catalyzed by six enzymes (SET1a and SET1b, MLL1-MLL4) whose specific functions are largely unknown. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22476432", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 373, 
                "text": "Epigenetic regulation of gene expression by covalent modification of histones is important for germ line cell development. In mammals, histone H3 lysine 9 (H3K9)-specific histone methyltransferases (HMTases), such as G9a, SETDB1, and SUV39H, play critical roles, but the contribution of H3K9-specific HMTases in Drosophila remains to be clarified, especially in male sperm."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18498648", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1972, 
                "offsetInEndSection": 2186, 
                "text": " Histone acetyltransferases (HATs), histone deacetylases (HDACs), kinases, and histone methyltransferases (HMTs) are all responsible for the addition/removal of covalent modifications on the histone tails [35-37]. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18498648", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2616, 
                "offsetInEndSection": 2927, 
                "text": "Histone methyltransferases (HMTs) can methylate arginine residues such as 2, 8, 17, and 26 on H3 and residue 3 on H4. HMTs can also methylate specific lysine residues such as 4, 9, 27, 36, and 79 on H3 and residue 20 on H4 which serve as markers for the recruitment of chromatin organization complexes [41-43]. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18498648", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3163, 
                "offsetInEndSection": 3266, 
                "text": " Historically, the methylation of H3-K9 has been linked to functionally repressed chromatin [33,44,45]."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22393255", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 288, 
                "offsetInEndSection": 566, 
                "text": "By analyzing the distribution of histone modifications in nuclei using quantitative fluorescence microscopy, we found that H4K16 acetylation (H4K16ac) is underrepresented and H4K20 monomethylation (H4K20me1) is enriched on hermaphrodite X chromosomes in a DCC-dependent manner. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/22357272", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 723, 
                "offsetInEndSection": 888, 
                "text": " Here, we found the epigenetic modification of the BZLF1 promoter in latent Raji cells by histone H3 lysine 27 trimethylation (H3K27me3), H3K9me2/me3, and H4K20me3. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20305384", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 144, 
                "offsetInEndSection": 441, 
                "text": "Although DNA methyltransferases have been shown to interact with histone methyltransferases such as EZH2 (which methylates histone H3 on lysine 27) and G9a (which methylates histone H3 on lysine 9), the relationship between DNA methylation and repressive histone marks has not been fully studied. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/20026581", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 1885, 
                "offsetInEndSection": 2154, 
                "text": "Np95 or its human homolog ICBP90/UHRF1 were reported to interact with the histone deacetylase HDAC1 and the histone methyltransferase G9a and to mediate silencing of a viral promoter, suggesting a role of Np95 in gene silencing through histone modification (13,23,24). "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/19571682", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 408, 
                "offsetInEndSection": 685, 
                "text": "Methylation of histone H4 lysine 20 (H4K20me) plays critical roles in diverse cellular processes such as gene expression, cell cycle progression and DNA damage repair, with each of the three degrees of methylation (mono-, di- and tri-methylation) making a unique contribution. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18846226", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 2901, 
                "offsetInEndSection": 3116, 
                "text": "The trithorax proteins Trithorax (TRX) and Absent, small or homeotic 1 (ASH1) also catalyze modifications of nucleosomal histones, including the methylation of lysine 4 of histone H3 (H3K4) [18],[19],[20],[21],[22]."
            }, 
            {
                "beginSection": "sections.1", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/18846226", 
                "endSection": "sections.1", 
                "offsetInBeginSection": 4182, 
                "offsetInEndSection": 4436, 
                "text": " It has been reported that both ASH1 and TRX methylate H3K4 [18],[19],[20]; this covalent modification of chromatin is enriched near the promoters of many genes and is thought to recruit factors required for early events in the transcription cycle [23]. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17584191", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 339, 
                "offsetInEndSection": 498, 
                "text": "Histone H3-lysine (K) 4, H3-K9 and H3-K27 modifications in all these four genes were examined by chromatin immunoprecipitation (ChIP) assay in HCC cell lines. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17548343", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 111, 
                "text": "The histone H4 N-terminal tail has long been regarded as a major regulator in chromatin structure and function."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/17468742", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 268, 
                "text": "Gene transcription is critically influenced by chromatin structure and the modification status of histone tails. Methylation of lysine residues in histone tails is dynamically regulated by the opposing activities of histone methyltransferases and histone demethylases."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16581777", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 145, 
                "text": "The SAS3-dependent NuA3 histone acetyltransferase complex was originally identified on the basis of its ability to acetylate histone H3 in vitro."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/16409643", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 3684, 
                "offsetInEndSection": 3932, 
                "text": "Consistent with the histone code, it has been revealed that the methylation of histone H3 lysine 9 (H3 K9), a modification associated with transcriptionally silent heterochromatin, is critical for long-range chromatin regulatory processes [26,27]. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/15775980", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 89, 
                "text": "SU(VAR)3-9 like histone methyltransferases control heterochromatic domains in eukaryotes."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690609", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 306, 
                "text": "Methylation of position-specific lysine residues in histone N termini is a central modification for regulating epigenetic transitions in chromatin. Each methylatable lysine residue can exist in a mono-, di-, or trimethylated state, thereby extending the indexing potential of this particular modification. "
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893173", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 126, 
                "offsetInEndSection": 259, 
                "text": "One of these modifications, histone lysine methylation, has been shown to be highly stable and to represent an epigenetic alteration."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/12154089", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 282, 
                "offsetInEndSection": 540, 
                "text": "Primarily because of the recent discovery of the SET domain-depending H3-specific histone methyltransferases SUV39H1 and Suv39h1, which selectively methylate lysine 9 of the H3 N terminus, this posttranslational modification has regained scientific interest."
            }, 
            {
                "beginSection": "title", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850410", 
                "endSection": "title", 
                "offsetInBeginSection": 0, 
                "offsetInEndSection": 154, 
                "text": "Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850410", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 899, 
                "offsetInEndSection": 1168, 
                "text": "Our results suggest that the methylation of histone tails can have distinct effects on transcription, depending on its chromosomal location, the combination of posttranslational modifications, and the enzyme (or protein complex) involved in the particular modification."
            }, 
            {
                "beginSection": "sections.0", 
                "document": "http://www.ncbi.nlm.nih.gov/pubmed/11316813", 
                "endSection": "sections.0", 
                "offsetInBeginSection": 164, 
                "offsetInEndSection": 363, 
                "text": "Among the different groups of enzymes known to catalyze the covalent modification, the most recent additions are the histone methyltransferases (HMTases), whose functions are now being characterized."
            }
        ], 
        "type": "summary"
    }
]}
